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ABSTRACT 
Angiogenesis plays a key role in the pathogenesis of haematological malignancies such as 
acute myeloid leukaemia (AML), multiple myeloma (MM) and lymphoma (NHL). The 
evidence supporting this theory includes the finding of increased bone marrow 
microvessel density and  increased levels of plasma and urinary pro-angiogenic cytokines 
in patients with these malignancies as well as encouraging results from preclinical and 
clinical studies using antiangiogenic therapies. A significant limiting factor in most of 
these studies has been the short half-life of most antiangiogenic compounds which has 
necessitated the use of cumbersome administration protocols resulting in poor compliance 
and an inability to administer the drug long enough to result in its desired therapeutic 
effect. The aim of this thesis therefore is to investigate the therapeutic effects of stable 
antiangiogenic expression in xenograft models of AML, NHL and MM. We investigated 
the antitumour effects of stably blocking the vascular endothelial growth factor (VEGF) 
pathway, the matrix metalloproteinase pathway and the use of interferons, a family of 
cytokines with significant antitumour activity resulting not only from their antiangiogenic 
properties but also from their anti-proliferative, anti-apoptotic and immunomodulatory 
effects. Murine models of AML, NHL and MM were developed by engrafting a number 
of well characterized tumour cell lines – HL-60, Raji and KMS12-BM respectively into 
β2mnull NOD/SCID immunodeficient mice, resulting in a tumour phenotype resembling 
the human disease. Blockade of the VEGF pathway was achieved by stably expressing 
the soluble form of the VEGF receptor (sFlk-1) using adeno associated viral vectors or by 
using an antibody directed against VEGF but neither strategy resulted in antitumour 
activity in AML or NHL xenograft models. We were however able to show that stable 
expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) resulted in significant 
antitumor activity against MM cells in vivo. Finally we were able to demonstrate for the 
first time that Interferon-β has profound antileukaemic activity in the setting of a 
xenograft model and that even low level expression when stable can significantly inhibit 
primary AML engraftment in vivo. 
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1.1 Angiogenesis - role in tumourigenesis 
Angiogenesis, the process of blood vessel formation from pre-existing vessels is essential 
for the female reproductive cycle, for tissue repair and wound healing. In addition many 
diseases are driven by persistent unregulated angiogenesis namely diabetic retinopathy, 
arthritis and ocular neovascularisation. It is now also clear that the growth and metastatic 
potential of most tumours, both solid and haematological, are angiogenesis dependent. 
Most tumours can persist in situ for a considerable period of time ranging from months to 
years without neovascularisation. Folkman first described the phenomenon by which 
dormant tumours become vascularised when a subgroup of cells within the tumour 
acquire an angiogenic phenotype. According to Folkman tumours upto 2-3 mm3 can exist 
in a prevascular phase but in order to further increase in size they require 
neovascularisation (Folkman, 1990). The switch to the angiogenic phenotype occurs as a 
result of a change in the local equilibrium between pro and antiangiogenic factors in the 
vicinity of the tumour. During this process proangiogenic factors such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and matrix 
metalloproteinases (MMPs) are overexpressed by tumour or stromal cells. In addition 
many of the endogenous inhibitors of angiogenesis such as angiostatin, interferons and 
tissue inhibitors of metalloproteinases (TIMPs) are downregulated. The net effect is to 
promote endothelial cell migration and proliferation. The tumour vasculature delivers 
oxygen and nutrients to proliferating tumour cells as well as releasing growth factors and 
cytokines, both of which facilitate tumour growth and metastases. 
 
1.2 Angiogenesis – role in haematopoiesis and haematological malignancies 
It is now recognised that the haematopoietic and vascular systems are linked closely by 
virtue of the fact that both systems appear to be derived from a common precursor called 
the haemangioblast which originates from the mesoderm in the developing embryo (Choi 
et al., 1998). Evidence supporting this hypothesis comes from studies showing that 
haematopoietic and endothelial cells share expression of a number of genes such as 
CD34, Flk-1, Flt-1, Tie-2 and SCL/TAL-1. Overexpression of the SCL/TAL-1 gene leads 
to excess production of  both haematopoietic and  endothelial cells in zebrafish models 
(Gering et al., 1998). CD34 enriched human peripheral blood cells were shown to have 
the ability to differentiate into endothelial cells in vitro (Asahara et al., 1997). In addition 
Shi et al were able to demonstrate that BM derived human CD34+ peripheral blood cells 
had the potential to differentiate into endothelial cells in a canine bone marrow 
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transplantation model (Shi et al., 1998). Asahara et al went one step further and showed 
that BM derived endothelial cell (EC) progenitors contributed to postnatal physiologic as 
well as pathological neovascularisation (Asahara et al., 1999). In these experiments 
syngeneic transgenic mice expressing β-galactosidase under the transcriptional regulation 
of an endothelial specific promoter were used as transplant donors. EC progenitors were 
identified in the endometrium of transplanted mice following induction of ovulation as 
well as in the vicinity of cutaneous wounds and in association with subcutaneously 
implanted colon carcinoma tumour cells. 
The process of angiogenesis in haematological malignancies is similar to that seen in 
solid tumours. Endothelial cells from pre-existing venules within the bone marrow are 
activated, proliferate, migrate and form new blood vessels which in turn supports tumour 
proliferation. Complex interactions take place between the neovasculature, tumour cells 
and the extracellular matrix mediated by growth factors, cytokines and by cell-cell 
contact in the bone marrow. Detailed evidence supporting the role of angiogenesis in 
acute myeloid leukaemia, myeloma and lymphoma includes the finding in these 
conditions of increased microvessel density and elevated levels of pro-angiogenic 
cytokines and the antitumour effects of antiangiogenic therapies, all of which are 
discussed in detail later in this chapter.  
 
1.3 Factors involved in angiogenesis 
A large number of pro and anti-angiogenic factors have been identified which play a role 
in regulating physiological and tumour induced angiogenesis (reviewed in (Bouis et al., 
2006)). Two of the more important groups of angiogenic factors - VEGF and MMPs will 
be discussed in more detail in this chapter.  
 
1.3.1 Vascular endothelial growth factor 
Vascular endothelial growth factor is the most well characterized proangiogenic factor 
and has atleast six isoforms (VEGF, PIGF, VEGF-B, VEGF-C, VEGF-D and VEGF-E), 
all of which are secreted as dimeric glyoproteins. They act through specific VEGF 
receptors - VEGFR-1 (Flt-1), VEGFR-2 (Flk-1) and VEGFR-3 as well as the accessory 
receptors Neuropilin-1 and Neuropilin-2.  
VEGF is one of the most potent proangiogenic factors known and has high specificity for 
the vascular endothelium. It is essential for the early development of the vasculature 
during embryogenesis with homozygous VEGF knockout mice showing embryonic 
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lethality due to defects in blood island formation (Ferrara, 2004). Furthermore knockout 
of the VEGFR-2 gene also leads to absence of blood vessels and non survival of the 
embryo (Shalaby et al., 1995) while absence of the VEGFR-1 gene results in severe 
impairment of functional blood vessel development (Fong et al., 1995). VEGF plays a 
major role in stimulating physiological angiogenesis. For instance development of retinal 
vasculature has been shown to be mediated by hypoxia induced VEGF expression by 
surrounding neuroglial cells (Stone et al., 1995). In addition VEGF induced angiogenesis 
plays an important role in wound healing (Brown et al., 1992) and in the pathogenesis of 
disorders such as diabetic retinopathy (Adamis et al., 1994). VEGF also appears to be the 
main inducer of tumour angiogenesis. Tumour hypoxia and oncogenes upregulate VEGF 
levels in the neoplastic cells as well as upregulate VEGFR-1 and VEGFR-2 receptors on 
tumour endothelial cells the net effect of which is to promote tumour progression. VEGF 
contributes to tumour angiogenesis firstly by stimulating endothelial cell proliferation and 
migration and secondly by rendering vessels hyperpermeable to plasma proteins leading 
to their extravastion and the formation of a matrix that supports blood vessel growth 
(Dvorak et al., 1999). There is now extensive evidence implicating VEGF in tumour 
angiogenesis related to myeloma, acute myeloid/lymphoid leukaemia and lymphoma 
which will be summarized later on in this chapter. Some of the factors that potentiate 
VEGF production include hypoxia-inducible factor (HIF-1), fibroblast growth factor, 
platelet derived growth factor, transforming growth factor-β, keratinocyte growth factor 
and interleukin-6. On the other hand cytokines such as IL-10 and IL-13 inhibit the release 
of VEGF. 
The biological activity of VEGF is mediated primarily through the VEGFR-1 and 
VEGFR-2 receptors. Both these receptors along with VEGFR-3 are transmembrane 
receptors with extracellular immunoglobulin like domains that bind VEGF and an 
intracellular tyrosine kinase domain through which the signaling cascade is activated. 
VEGFR-1 and VEGFR-2 are expressed predominantly on endothelial cells in contrast 
with VEGFR-3 which is found on lymphatic vessels. VEGFR-1 is also expressed on 
trophoblast cells, monocytes and renal mesangial cells whilst VEGFR-2 is also found on 
haematopoietic stem cells, megakaryocytes, retinal progenitor cells. Activation of both 
VEGFR-1 and -2 receptors results in endothelial cell migration although only VEGFR-2 
activation appears to induce endothelial cell proliferation. Neuropilin-1 is also important 
for angiogenesis by acting as a VEGF coreceptor which potentiates the binding of VEGF 
to VEGFR-2 resulting in an enhanced endothelial cell migratory response (Soker et al., 
19 
 
1998). Similarly neuropilin-2 has been shown to be a coreceptor for certain VEGF 
isoforms, again enhancing their biological response (Favier et al., 2006). 
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Figure 1.1 Schematic diagram showing interaction of VEGF ligands with their 
receptors - taken from  (Hicklin and Ellis, 2005) 
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1.3.2 Matrix metalloproteinases and Tissue inhibitors of metalloproteinases 
The matrix metalloproteinases (MMPs) are a family of zinc dependent proteolytic 
enzymes that degrade components of the extracellular matrix thereby facilitating 
endothelial cell migration and tubule formation. There are over 25 MMPs all of which 
share a common catalytic domain but with varying specificities determined by a 
regulatory subunit, the hemopexin domain. Five major groups can be seen based on their 
substrate specificity – collagenases, gelatinases, stromelysins, membrane-type 
metalloproteinases and the others. The majority of the MMPs are secreted as inactive 
proteins which are activated following cleavage of the N-terminal pro-domain. Tissue 
inhibitors of matrix metalloproteinases (TIMPs) regulate the activity of the MMPs. Four 
TIMPs (TIMP 1-4) have been identified each of which has a different pattern of MMP 
inhibition. 
 
  
Figure 1.2 Schematic diagram showing the domain structure of the matrix 
metalloproteinases 
 
The primary function of MMPs is to break down the extracellular matrix barrier which 
enables endothelial cells as well as tumour cells to invade through the stroma (Nagase and 
Woessner, 1999). MMPs can also stimulate endothelial cell proliferation either directly 
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(Nishizuka et al., 2001) or by releasing growth factors like VEGF sequestered in the 
extracellular matrix (Bergers et al., 2000).  They also affect endothelial cell attachment by 
cleaving vascular endothelial cadherin which plays a crucial role in cell-cell adhesion 
(Herren et al., 1998). MMPs can paradoxically also have an antiangiogenic effect by 
releasing angiogenesis inhibitors such as angiostatin from the extracellular matrix 
(Cornelius et al., 1998).  
The gelatinase family of MMPs which include MMP-2 and MMP-9 have been studied 
extensively with considerable evidence supporting their integral involvement in tumour 
related angiogenesis. A number of studies have linked elevated levels of MMP-2 and 
MMP-9 to increased metastasis and tumour stage (Hanemaaijer et al., 2000; Schmalfeldt 
et al., 2001). MMP-2 and 9 expression is increased in invasive cell lines compared with 
non invasive types. Overexpression of MMP-2 and MMP-9 increased tumour metastasis 
in immunodeficient mice. In addition suppression of MMPs using recombinant TIMPs or 
synthetic MMP inhibitors resulted in inhibition of tumour growth and metastasis.  
TIMPs are the endogenous regulators of MMPs and the balance between the level of 
active MMPs and TIMPs helps determine the extent of angiogenesis. All four known 
TIMPs inhibit specific MMPs with TIMP-3 having a broader spectrum of action that 
includes the ADAM family of metalloproteinases. TIMPs also have the ability to both 
promote as well as inhibit apoptosis of a number of cell types including tumour cells. 
TIMP-1 for instance enhances the proliferation of keratinocytes, fibroblasts and Raji 
lymphoma cells (Hayakawa et al., 1992). Timp-2 also has similar growth promoting 
properties (Hayakawa et al., 1994). On the other hand overexpression of TIMP-1 or -2 
results in a reduction in tumour growth presumably because their MMP inhibitory 
properties come into effect (Gomez et al., 1997). Overexpression of TIMP-3 induces 
apoptosis of a number of tumour cell lines and vascular smooth muscle cells (Ahonen et 
al., 1998; Baker et al., 1998). TIMP-3 uniquely amongst the TIMPs has the ability to 
inhibit angiogenesis directly by competitively binding the VEGFR-2 receptor. (Qi et al., 
2003) 
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Figure 1.3 Schematic diagram showing the interplay between MMPs and Timps in 
cancer progression 
 
1.4 Angiogenesis in multiple myeloma 
Bone marrow angiogenesis, as measured by microvessel density (MVD), has been shown 
to be markedly elevated in myeloma compared to its premalignant state, monoclonal 
gammopathy of unknown significance (MGUS) (Vacca et al., 1994). The increase in 
angiogenesis was found to correlate with the plasma cell proliferative rate rather than 
plasma cell number. Bone marrow angiogenesis has also been shown to have prognostic 
value in myeloma (Rajkumar et al., 2000; Sezer et al., 2000). Vacca et al showed that 
overall survival in patients with newly diagnosed myeloma was significantly different 
among those with high, intermediate and low grade angiogenesis with median times of 2, 
4 and 4.4 yrs respectively. Munshi showed a correlation between high MVD and poor 
event free survival, overall survival and duration of complete response in patients with 
myeloma treated with standard induction chemotherapy followed by tandem 
autotransplants and interferon maintainance (Munshi and Wilson, 2001). Similarly MVD 
also predicts overall survival following autologous transplantation with a median overall 
survival from diagnosis of 40 months for those with high grade angiogenesis compared 
with a significantly higher figure for those with low grade angiogenesis (Kumar et al., 
2004). Interestingly angiogenesis appears to persist even after treatment with 
chemotherapy, autologous tranplantation or even the use of antiangiogenic agents such as 
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thalidomide (Kumar et al., 2002; Rajkumar et al., 1999; Singhal et al., 1999). Sezer 
however has shown that MVD in patients with myeloma who did achieve remission with 
treatment was significantly lower than pre-treatment levels (Sezer et al., 2001b). Overall 
these studies suggest that angiogenesis plays a part in the transformation of MGUS to 
myeloma and in the progression of early stage myeloma to advanced refractory disease. 
As with other tumours induction of angiogenesis in myeloma is thought to be mediated by 
an alteration in the balance between pro and anti-angiogenic cytokines. A number of pro-
angiogenic cytokines are upregulated in patients with active myeloma. VEGF is one of 
the key pro-angiogenic cytokines thought to play a role in myeloma pathogenesis. VEGF 
was shown to be overexpressed in plasma cells from myeloma patients with an increase in 
VEGF receptors in the surrounding stromal cells (Bellamy et al., 1999; Dankbar et al., 
2000).  Similarly Ribas et al demonstrated significantly increased VEGF immunostaining 
in bone marrow biopsies from myeloma patients which had prognostic impact on overall 
and event free survival on univariate analysis but not on multivariate analysis (Ribas et 
al., 2004). On the other hand Molina et al were unable to demonstrate increased VEGF 
expression in myeloma cells either by immunohistochemistry or by real time reverse 
transcriptase polymerase chain reaction studies. Although serum VEGF levels have not 
been shown to be elevated in myeloma, they are significantly elevated in patients with 
POEMS syndrome (Soubrier et al., 1997), a plasma cell disorder related to myeloma. 
Serum levels of another proangiogenic factor basic fibroblast growth factor (bFGF) were 
also shown to be elevated in myeloma by Sezer et al (Sezer et al., 2001a) and these levels 
decreased with effective chemotherapy. Matrix metalloproteinases (MMPs) play a key 
role in degrading the extracellular matrix surrounding tumour cells thereby facilitating the 
proliferation and migration of endothelial cells. Myeloma cells can not only produce pro-
MMPs but also stimulate stromal cells including endothelial cells to produce MMPs. 
Barille et al showed that myeloma cells produce MMP-7 which in addition to its direct 
proteolytic activity on the extracellular matrix, also converts pro-MMP-2 produced by 
stromal cells to its active form (Barille et al., 1999). Myeloma cells were also shown to 
express MMP-2 and -9 with surrounding tumour cells secreting MMPs-1 and -2 (Barille 
et al., 1997). 
A number of antiangiogenic therapeutic strategies have been evaluated in myeloma with 
varying degrees of efficacy but the results overall further confirm the role of angiogenesis 
in the pathogenesis of myeloma. The discovery by Barlogie’s group that thalidomide, a 
drug with potent antiangiogenic properties, was highly effective in patients with relapsed, 
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refractory myeloma (Singhal et al., 1999) led to a number of other antiangiogenic 
compounds being developed for use in myeloma. Lenalidomide, an analogue of 
thalidomide, has shown greater efficacy than thalidomide in myeloma with reduction in 
angiogenesis through inhibition of VEGF secretion being one of its mechanisms of action 
(Rao, 2007).  The proteosomal inhibitor Bortezomib is now well established in the 
treatment of myeloma and in addition to its proteosomal inhibitory effects it has been 
shown to have significant inhibitory effects on endothelial cell proliferation and migration 
as well as to downregulate VEGF and angiopoietin expression by endothelial cells 
(Roccaro et al., 2006). In view of the integral part that VEGF is thought to play in tumour 
angiogenesis several inhibitors of the VEGF signaling pathway have been developed. 
Bevacizumab, a humanized monoclonal antibody against VEGF and approved for the 
treatment of colorectal carcinoma is now being evaluated in myeloma. Initial studies with 
VEGF receptor  tyrosine kinase inhibitors including	   PTK787/ZK222584 (Novartis) and  
GW654652 (GlaxoSmithKline) showed some anti myeloma efficacy in vitro (Podar and 
Anderson, 2005). Pazopanib is a novel small molecule tyrosine kinase inhibitor of VEGF 
receptors -1, -2 and -3 which has shown antiangiogenic and anti-myeloma effects in a 
xenograft mouse model. Phase 1/11 studies using this compound in myeloma patients are 
ongoing (Podar et al., 2006). Bisphosphonates are another class of drugs that have proven 
efficacy against myeloma bone disease as well as having direct antitumour effects in 
myeloma. Furthermore it is now clear that they also have significant antiangiogenic 
effects by inhibiting VEGF and VEGFR expression (Scavelli et al., 2007). 
 
1.5 Angiogenesis in leukaemias 
There is increasing evidence now supporting a role for angiogenesis even in acute 
myeloid and lymphoid leukaemias. MVD was found to be raised in bone marrow biopsies 
from patients with acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), 
chronic lymphocytic leukaemia (CLL) and chronic myelomonocytic leukaemia (CMML) 
(Aguayo et al., 2000; Hussong et al., 2000). Perez-Atayade et al showed evidence of 
increased MVD in the bone marrow of children with acute lymphoblastic leukaemia 
(ALL) (Perez-Atayde et al., 1997).  
Numerous preclinical studies have also demonstrated the close relationship between 
angiogenesis and leukaemia cell survival. Human ALL cells injected into non-obese 
diabetic severe combined immunodeficiency (NOD/SCID) mice induce bone marrow 
neovascularisation (Veiga et al., 2006). Furthermore bone marrow endothelial cells when 
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exposed to plasma from patients with ALL were shown to undergo proliferation, 
migration and tube formation, none of which occurred following exposure to plasma from 
normal patients (Veiga et al., 2006). Co-culture of ALL cells with bone marrow 
endothelial cells significantly reduced leukaemia cell apoptosis when compared with ALL 
cells cultured in control conditions. These experiments strongly support the hypothesis 
that leukaemia cells induce angiogenesis which in turn promotes leukaemia cell survival 
and expansion. Further evidence supporting the biological relationship between 
leukaemia and angiogenesis comes from the observation that leukaemic cells home to 
bone marrow vascular niches mediated by stromal derived factor 1 (SDF-1) and its 
receptor CXCR4 (Sipkins et al., 2005).  SDF-1 is highly expressed by endothelial cells in 
these bone marrow vascular niches and CXCR4 is highly expressed on ALL cells. 
Fiedler et al showed that in most patients with AML, VEGF is expressed by leukaemic 
blasts (Fiedler et al., 1997). Cellular VEGF levels were shown to be higher in AML than 
in normal bone marrow and found to have prognostic significance (Aguayo et al., 1999). 
There was a correlation between higher VEGF levels and shortened overall and disease 
free survival. VEGF receptors have also been demonstrated on leukaemic blasts 
suggesting that leukaemia cell survival and/or proliferation may be maintained, atleast 
partly, by an autocrine VEGF pathway (Dias et al., 2000). Expression of the VEGF 
receptor neuropilin-1 (NRP-1) in bone marrow is significantly increased in AML patients, 
with high expression correlating with poor overall survival. 5yr OS rates were 16.9% in 
patients with high NRP-1 levels compared with 49.6% in those with low levels (Kreuter 
et al., 2006). Different patterns of angiogenic factor expression can be recognized 
between the different haematological malignancies suggesting they may play different 
roles depending on the type of leukaemia. For instance plasma VEGF levels were not 
elevated in MDS or ALL (Aguayo et al., 2000). However Koomagi et al did show 
elevated levels of VEGF in childhood ALL with a trend to longer relapse free and overall 
survival in patients with low VEGF levels (Koomagi et al., 2001). Bellamy et al studied a 
panel of haematopoietic cell lines and found about 50% expressed bFGF compared with 
100% that expressed VEGF (Bellamy et al., 1999). Elevated plasma and urinary levels of 
bFGF were detected in urine from patients with ALL and elevated bFGF levels correlated 
with increased bone marrow vasulature (Perez-Atayde et al., 1997). Interestingly bFGF 
levels failed to significantly diminish with clinical remission.  
As with myeloma, expression of the metalloproteinases MMP-2 and -9  is upregulated in 
both adult and childhood ALL with MMP-2 positivity correlating with the presence of 
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extramedullary disease in adult ALL (Kuittinen et al., 2001). MMP-2 expression of ALL 
cell lines correlated with the ability to invade matrigel in vitro and with the capacity to 
invade and metastasize in a SCID mouse model (Hendrix et al., 1992). MMP-9 
expression in lymphoblastic cell lines was also found to be important for invasion and 
metastasis in Matrigel assays (Ivanoff et al., 1999). The role of MMP-2 and -9 in AML is 
more complex with variable expression levels of MMP-2 and -9 being seen in the 
conditioned media of myeloid cell lines and in blasts from AML patients (Janowska-
Wieczorek et al., 1999). In vitro Matrigel assays show that invasion of myeloid cells 
through Matrigel can be inhibited by the natural metalloproteinase inhibitor TIMP-2 and 
by a blocking antibody against MMP-2 but not by an anti MMP-9 antibody suggesting 
that myeloid cell invasion was largely dependent on MMP-2 activity (Sawicki et al., 
1998). In a study by Kuittinen et al MMP-2 expression strongly correlated with good 
prognosis in AML patients (3yr EFS = 82% for MMP-2 positive patients compared with 
median EFS of 13.5 months for MMP-2 negative patients) (Kuittinen et al., 1999). In 
contrast Lin et al found significantly lower plasma MMP-9 levels  in patients with AML 
compared with normal controls and this also correlated with improved overall survival 
(>12 months in those with low levels compared with 4 months when MMP-9 levels were 
high) (Lin et al., 2002). MMP-9 levels were no different to controls when patients were in 
complete remission but levels were shown to drop again at the time of relapse.  
A number of different antiangiogenic molecules have been evaluated in leukaemia 
patients with mixed results. Thalidomide when used in combination with other 
chemotherapeutic agents has shown only modest efficacy in AML with complete 
response rates of upto 25% (Barr et al., 2007; Steins et al., 2003). Clinical trials with 
single agent Bevacizumab in patients with relapsed/refractory AML showed a reduction 
in bone marrow VEGF expression but no significant antileukaemia effect (Zahiragic et 
al., 2007). A phase II trial of Bevacizumab used in combination with cytarabine and 
mitoxantrone has shown encouraging results (ORR 48%, CR 33%, PR 14.5%) in patients 
with relapsed/refractory AML with a reduction in serum VEGF levels and bone marrow 
MVD following treatment (Karp et al., 2004). Several small molecule tyrosine kinase 
inhibitors of the VEGF and PDGF pathways have also been used to treat patients with 
AML. SU5416 (inhibitor of VEGFR-1,-2, c-kit and Flt-3 receptors) when used on its own 
to treat patients with refractory AML resulted in an overall response rate of 19% (Fiedler 
et al., 2003). PTK787 (inhibitor of VEGFR-1,-2,-3, PDGFR and c-kit receptors) failed to 
demonstrate efficacy when used as monotherapy to treat relapsed AML but in 
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combination with cytarabine and daunorubicin resulted in a complete remission rate of 
29% (5 out of 17 patients) (Roboz et al., 2006). 
 
1.6 Angiogenesis in lymphomas 
MVD is increased in low and high grade non Hodgkins lymphomas compared with 
benign lymphadenopathies (Ribatti et al., 2000). Increased MVD has also been shown in 
involved organs from patients with adult T cell leukaemia/lymphoma compared to normal 
controls (Kchour et al., 2008). Jorgenson et al reported on a large study of non Hodgkins 
lymphoma patients including peripheral T-cell (PTCL), follicular and diffuse large B-cell 
lymphoma and showed increased MVD in all subtypes with high interfollicular MVD 
scores predicting poorer overall and event free survival in follicular lymphoma 
(Jorgensen et al., 2007). In contrast Koster et al showed that increased MVD was 
associated with a favourable outcome in patients with FL receiving first line treatment 
(Koster et al., 2005). One possible explanation for this contradictory finding is the use of 
interferon-α (IFN-α) in the treatment of this patient group with those patients with a 
higher MVD possibly responding better to IFN-α, a potent antiangiogenic agent. Tzankov 
et al evaluated angiogenesis parameters in DLBCL, FL and mantle cell lymphoma and 
found that the aggressive lymphomas had the highest MVD and  VEGF expression but 
failed to demonstrate any correlation with clinical outcome (Tzankov et al., 2007). 
Similarly Hazar et al failed to show any prognostic significance for MVD in patients with 
NHL (Hazar et al., 2003). Passalidou et al argued that the phenotype of angiogenesis was 
more important than MVD when comparing high grade and low grade lymphomas with 
more immature vasculature in DLBCL compared with a more mature vascular phenotype 
in FL (Passalidou et al., 2003). In a smaller study on HL, Mainou-Fowler showed 
increased MVD in lymph node biopsies along with increased VEGF expression (Mainou-
Fowler et al., 2006). Further proof of the role of angiogenesis in HL comes from 
Glimelius et al who have shown significantly worse progression free survival (PFS) in 
patients with high MVD compared with those with low MVD (Glimelius et al., 2005). In 
a large study of 286 patients with HL, MVD was found to be an independent adverse 
prognostic factor in relation to disease free survival (Korkolopoulou et al., 2005). 
In Jorgenson’s study of NHL patients VEGF expression was also found to be increased, 
by immunohistochemistry, in all subtypes with the highest expression seen in PTCL. The 
pattern of VEGF expression (diffuse versus focal) was found to have prognostic 
significance with diffuse expression associated with worse overall survival in FL. VEGF 
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expression has also been shown to correlate with tumour grade - DLBCL patients show 
higher VEGF expression in comparision with low grade lymphoma (Ho et al., 2002). 
High serum VEGF levels were shown to correlate with poor prognosis in non Hodgkins 
lymphoma (Salven et al., 1997). Passam also showed increased serum VEGF expression 
in untreated patients with non Hodgkins lymphoma compared to normal controls with no 
significant decrease in levels even with successful treatment (Passam et al., 2008). 
Bertolini et al in a study of NHL patients showed an inverse correlation between serum 
VEGF levels and event free survival (Bertolini et al., 1999). Significantly increased 
VEGF expression has also been demonstrated in Hodgkins lymphoma, 
angioimmunoblastic lymphoma and Castleman’s disease either by immunohistochemistry 
(Doussis-Anagnostopoulou et al., 2002), insitu hybridisation (Foss et al., 1997) or serum 
ELISA (Rueda et al., 2007). Evaluation of preclinical lymphoma models have revealed a 
correlation between the extent of VEGF production by lymphoma cell lines in vitro and 
the efficiency of tumour engraftment in immunodeficient mice (Fusetti et al., 2000). 
Serum levels of bFGF were shown to be elevated in patients with NHL and high 
pretreatment levels were found to be associated with poor  overall survival (5 yr OS of  
39% in high bFGF expressors compared with 60% in low expressors) (Salven et al., 
1999). In this study multivariate analysis showed that bFGF had a stronger prognostic 
value than serum lactate dehydrogenase. These findings were corroborated by Pazgal et al 
who showed that patients with NHL who expressed bFGF had a significantly worse 
progression free and overall survival than those who did not96. In addition those patients 
expressing the bFGF receptor-1 were significantly less likely to achieve a complete 
remission than those lacking the receptor (33% v 67%, p=0.047) 
 Diffuse large B-cell lymphoma (DLBCL) patients with high levels of tissue MMP-9 
were found to have significantly worse overall survival than those patients who did not 
express MMP-9 (Sakata et al., 2004). In follicular lymphoma, MMP-2 and MMP-9 
expression was found to correlate with higher grade disease with MMP-9 positivity 
predictive of good chemotherapy response although it failed to have prognostic 
significance (Pennanen et al., 2008). In Hodgkins lymphoma, MMP-9 was expressed by 
Reed Sternberg cells but again this did not correlate with overall survival (Flavell et al., 
2000). 
Circulating endothelial progenitor cells were found to correlate with tumour volume in a 
lymphoma xenograft model (Monestiroli et al., 2001).  Igreja et al showed that circulating 
EPCs were seen more frequently in lymphoma patients than in healthy controls, with 
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higher numbers found in younger patients and in those with aggressive lymphomas 
(Igreja et al., 2007). Levels of EPCs declined with successful treatment of the lymphoma. 
Bevacizumab has shown modest clinical activity  in NHL when used as a single agent or 
in combination with R-CHOP chemotherapy (Ganjoo et al., 2006). There was also a 
marginal correlation between baseline VEGF levels and response to treatment in this 
study. Antisense oligonucleotides against VEGF have also been used to treat lymphoma 
patients, with a reduction in plasma VEGF levels after treatment and limited efficacy 
(Levine et al., 2006). Thalidomide as well as its analogue lenalidomide have shown 
significant activity against indolent lymphomas like mantle cell lymphoma when used as 
monotherapy or in combination with chemotherapy (Kaufmann et al., 2004; Smith et al., 
2008). Low dose ‘metronomic’ therapy appears to target the tumour vasculature rather 
than directly inhibiting tumour proliferation and this approach has been shown to be 
successful in DLBCL (Buckstein et al., 2006). In this study where celecoxib and low dose 
cyclophosphamide were used to treat relapsed DLBCL patients, clinical response was 
seen in 37% of patients and this correlated with declining levels of EPCs. Sunitinib (a 
broad inhibitor of VEGFR-1,2 and 3 and PDGF receptors) has shown promise in 
lymphomas and is currently being evaluated in phase II trials for DLBCL (Buckstein et 
al., 2007). 
 
1.7 Antiangiogenic therapy for haematological malignancies 
With significant evidence emerging to support a critical role for angiogenesis in the 
pathogenesis of haematological malignancies, there has been increasing interest in 
developing antiangiogenic therapeutic strategies for these disorders. There are several 
theoretical reasons why targeting the neovasculature may be advantageous.  Delivery of 
anti-cancer drugs to tumour cells is often impaired because of abnormalities in blood flow 
arising from altered tumour blood vessel architecture and function. In contrast to tumour 
cells, the endothelial cells lining the tumour blood vessels are more readily accessible to 
therapy. Furthermore endothelial cells unlike tumour cells are homogenous and 
genetically stable and less likely to develop mutations causing resistance to drugs 
(Kerbel, 1991). Also the same drug can potentially be used to treat a range of 
malignanices when endothelial cells rather than the tumour cells are the target. 
As highlighted earlier angiogenesis is a complex process with multiple, sequential and 
interdependent steps. Four broad categories of antiangiogenic drugs can be described 
based on which step of the angiogenesis process is the target for inhibition. These include 
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(1) inhibitors of endothelial cell activation, (2) inhibitors of endothelial cell proliferation 
and migration, (3) drugs that inhibit the degradation of the extracellular matrix and (4) 
inhibitors of the integrin receptors. The majority of drugs that inhibit endothelial cell 
activation target the VEGF pathway – either as monoclonal antibodies binding VEGF 
(Bevacizumab) or the VEGFR-2 receptor (DC101) or as small molecule tyrosine kinase 
inhibitors of the VEGR receptors which include SU5416 (blocks VEGFR-2), SU6668 
(blocks VEGF, bFGF and PDGF receptors) and ZD4190 (blocks VEGFR-1 and VEGFR-
2 receptors). All of these drugs have shown efficacy in preclinical tumour models and are 
currently in phase II and phase III clinical trials. The second category of antiangiogenic 
drugs inhibits the proliferation and migration of endothelial cells. They include TNP-470, 
thalidomide, angiostatin and endostatin amongst others. Thalidomide is a potent 
antiangiogenic agent that targets multiple angiogenic pathways. When used as a single 
agent in myeloma it produces a partial response (50% paraprotein reduction) in atleast 
30% of patients (Singhal et al., 1999). In combination with dexamethasone it results in a 
response rate of 63% compared with 41% when given dexamethasone alone (Rajkumar et 
al., 2006). Thalidomide in combination with Rituximab results in a complete response 
rate of 31% in relapsed/refractory mantle cell lymphoma (Kaufmann et al., 2004). 
Similarly it has been shown to be effective when combined with fludarabine treatment in 
CLL, with overall response rates of 80% for previously untreated and 25% for relapsed 
patients (Giannopoulos et al., 2009). Several drugs that inhibit degradation of the 
extracellular matrix (MMP inhibitors) have been evaluated in a number of tumours 
including myeloma with limited success (Vihinen and Kahari, 2002). The reasons for this 
include the lack of selectivity of the MMP inhibitors, insufficient knowledge of which 
MMPs play the most crucial role in tumourigenesis, the use of these drugs in end stage 
disease where angiogenesis may be less important, the use of single agent therapy as 
opposed to adjuvant therapy and dose limiting toxicity. The final group of antiangiogenic 
drugs include inhibitors of the integrins, which play an important role in activating 
numerous signaling pathways that promote endothelial cell proliferation and migration. 
Several inhibitors of integrins are currently in clinical trials for example alpha4 integrin 
inhibitors in myeloma. 
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Drug Target Study entities Approved for 
Receptor tyrosine 
kinase inhibitors 
      
PTK787/ZK 222584 
(Vatalanib®) 
VEGFR1-3, 
PDGFRβ, c-Kit 
AML, PMF, MDS, 
CML, DLBCL, MM 
  
SU5416 
(Semaxinib) 
VEGFR1-2, c-kit, 
Flt3 
AML, MDS, MM, 
MPN 
  
Sorafenib (Nexavar®) VEGFR2-3, B-
Raf, Faf-1, 
PDGFRβ 
AML, ALL, MDS, 
CML, CLL, NHL, 
MM 
Advanced renal cell 
carcinoma, HCC 
Sunitinib (Sutent®) VEGFR1-3, 
PDGFRα+β, c-kit, 
Flt3 
AML, MDS, CLL, 
Myeloma, NHL 
Advanced renal cell 
carcinoma, GIST 
PKC-412 
(Midostaurin) 
VEGFR2, PKC, 
PDGFR, Flt3, c-
Kit 
AML   
Cediranib 
(Recentin®) 
VEGFR1-3, 
PDGFRβ, c-Kit 
AML, MDS, CLL   
Proteasome inhibitors       
Bortezomib 
(Velcade®) 
26S proteasome, 
NF-κB 
AML, ALL, MDS, 
CML, NHL, MCL 
MM, MCL 
Anti-VEGF strategies       
Bevacizumab 
(Avastin®) 
VEGF-A AML, MDS, CLL, 
CML, NHL, MM 
 Metastatic colorectal 
cancer, NSCLC, breast 
cancer 
Immunomodulatory 
drugs 
      
Thalidomide bFGF, VEGF, IL-
6 
AML, MDS, MPN, 
CLL, NHL, MM 
MM 
Lenalidomide 
(Revlimid®) 
bFGF, VEGF, IL-
6 
AML, MDS, CLL, 
NHL 
MM, 5q- MDS 
 
Table 1.1 Selection of ongoing clinical trials with antiangiogenic therapies for 
haematological malignancies 
(adapted from  (Medinger and Mross, 2010))  
 
1.8 Interferons   
Interferons (IFNs) are a family of cytokines with multiple biological effects including 
antiangiogenesis. Other key actions include inhibition of tumour cell proliferation, 
immunomodulation and regulation of antiviral responses. Two major classes of 
interferons have been described – types I and II based on their ability to bind to distinct 
receptor types. The common type I interferons include IFN-α, IFN-β, IFN-ω and IFN-τ, 
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all of which bind to the type I IFN receptor. IFN-γ is the sole type II IFN and binds to a 
distinct type II receptor. 
 
1.8.1 Apoptotic effects of Interferons 
The antitumour effects of IFNs also result from their ability to induce apoptosis in tumour 
cells as well as endothelial cells. The primary mechanism of IFN induced apoptosis is 
thought to be activation of the caspase pathway. IFNs upregulate death receptor ligands 
such as TNF related apoptosis inducing ligand (TRAIL) and Fas which bind to their 
respective receptors thereby activating Fas-associated death domain protein (FADD) 
which in turn activates caspase-8 leading to activation of the caspase cascade (Thyrell et 
al., 2002). It has also been postulated that caspase-9 can be independently activated 
through the release of cytochrome c triggered by IFN mediated mitochondrial activation 
(Thyrell et al., 2002). Other pathways shown to be involved in IFN induced apoptosis 
include increased activity of serine-threonine protein phosphatase 2A (Saydam et al., 
2003) and upregulation of TNF-α (Baker et al., 2002). Induction of apoptosis by IFNs is 
cell type dependent and the magnitude of the response can vary between the different IFN 
species. For instance IFN-β has a greater pro-apoptotic effect than IFN-α or IFN-γ against 
melanoma, ovarian carcinoma and multiple myeloma cell lines (Chawla-Sarkar et al., 
2001; Chen et al., 2001; Morrison et al., 2001). Resistance to the apoptotic effects of IFNs 
can arise from tumour mediated inhibition of pro-apoptotic IFN stimulated genes such as 
XAF-1 (X-linked inhibitor of apoptosis protein (XIAP) associated factor-1) or 
overexpression of inhibitory proteins like XIAP.  
 
1.8.2 Antiproliferative activity of Interferons 
IFNs induce a number of different genes some of which have been shown to regulate cell 
proliferation such as 2’5’ oligoadenylate synthetase (2-5A) and dsRNA-dependent protein 
kinase (PKR) (Lengyel, 1993). In addition, extracellular signal-regulated kinase (ERK) 
and mitogen-activated ERK- regulating kinase (MEK) play a critical role in regulating 
cell proliferation through their effects on the cell cycle by promoting degradation of 
mitotic inhibitors (p21WafI and p27KipI) and downregulating the cyclin-dependent kinases 
(Cdk -2 and -4). Type I IFNs have been shown to inhibit the MEK-ERK pathway 
resulting in impairment of cell cycle progression and ultimately a reduction in cell 
proliferation (Romerio and Zella, 2002). Other mechanisms that contribute to the 
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antiproliferative activity of IFN include increased cell rigidity, depletion of essential 
metabolites and suppression of proto-oncogenes (Marth et al., 1992). 
The antiproliferative effects of IFNs against malignancies have been demonstrated in a 
wide variety of solid tumour cell lines in vitro (Borden et al., 1982). With respect to 
haematological malignanices, IFNs are known to inhibit the proliferation of AML, ALL 
(Lee et al., 2010), myeloma (Einhorn et al., 1988) and lymphoma cells (Leandersson and 
Lundgren, 1980)  in both primary cells and cell lines. 
 
1.8.3 Immunomodulatory function of Interferons 
IFNs have long been known to have profound immunomodulatory activity involving both 
innate and adaptive immune responses. Type I IFNs are responsible for activating 
macrophages, natural killer cells and cytotoxic T cells as well as stimulating a Th1 T 
helper response (Goodbourn et al., 2000). They also have anti-inflammatory properties by 
inhibiting production of tumour necrosis factor-α, interleukin-8 and stimulating 
production of interleukin-10. 
 
1.8.4 Antiangiogenic effects of Interferons 
There is now considerable evidence demonstrating that IFNs have significant 
antiangiogenic activity either by their direct inhibitory effects on endothelial cells or 
indirectly by downregulating tumour derived pro-angiogenic cytokines. Several 
investigators have shown that type I and II IFNs inhibit proliferation of endothelial cells 
in vitro (Feldman et al., 1988; Minischetti et al., 2000; Ruszczak et al., 1990). Others 
however have challenged this view by reporting increased proliferation of endothelial 
cells after IFN-α treatment (Cozzolino et al., 1993; Gomez and Reich, 2003). Pammer et 
al postulated that the antiangiogenic activity of IFN-α resulted from endothelial cells 
undergoing replicative senescence, with this phenomenon only being seen after prolonged 
exposure to IFN-α (Pammer et al., 2006). Sgonc et al have demonstrated increased 
apoptosis of ECs in response to IFN-α (Sgonc et al., 1998). In addition IFN-α and β 
inhibit endothelial cell migration and invasion as well as formation of capillary-like 
structures in Matrigel assays (Albini et al., 2000). 
IFNs also inhibit angiogenesis indirectly by downregulating the production of pro-
angiogenic cytokines by tumour cells and stromal cells. Reduced VEGF expression in 
response to IFN-α and -β has been shown in hepatocellular carcinoma (Wu et al., 2005), 
neuroendocrine tumours (Rosewicz et al., 2004), Ewings tumour (Sanceau and 
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Wietzerbin, 2004), neuroblastoma (Streck et al., 2004) and peripheral blood mononuclear 
cells (Salven et al., 2001). Similarly IFN-α and -β downregulate expression of bFGF in 
bladder carcinoma (Dinney et al., 1998), colon carcinoma (Ozawa et al., 2001), renal cell 
carcinoma (Vermeulen et al., 1997) and neuroblastoma (Streck et al., 2004). Production 
of the matrix metalloproteinases MMP-2 and MMP-9 are also suppressed by type I and II 
IFNs in a variety of tumour cell lines (Fabra et al., 1992; Gohji et al., 1994; Kato et al., 
1995). 
The net result of the direct and indirect antiangiogenic effects of IFNs is inhibition of 
tumourigenesis. This has been demonstrated in both preclinical tumour models and in 
clinical trials. Experiments involving xenograft models of bladder carcinoma, 
neuroblastoma, prostate carcinoma and Ewings sarcoma have shown significant tumour 
regression in vivo when exposed to IFN-α/β along with a reduction in microvessel 
density. The antitumour effects of IFN were apparent when recombinant protein was 
administered parenterally as well as following viral mediated expression of IFN either 
systemically or from tumour cells. Sidky et al also showed that the antiangiogenic effects 
of IFN were independent of its antiproliferative effects ie, inhibition of angiogenesis did 
not occur solely as a result of a reduction in tumour cell mass. Experiments in a murine 
bladder carcinoma and  murine leukaemia model indicated that the reduction in 
microvessel density following treatment with murine IFN-β resulted not from any 
antiproliferative effects against the tumour cells but most likely from direct inhibition of 
angiogenesis pathways (Sidky and Borden, 1987). 
 
1.8.5 Therapeutic use of Type I Interferons in clinical trials 
Type I interferons have been used in humans to treat a variety of malignancies with 
mixed results. IFN-α has been extensively used in renal cell carcinoma either as 
monotherapy (Minasian et al., 1993) or in combination with interleukin-2 (Negrier et al., 
1998) and 5-Fluorouracil (Hofmockel et al., 1996) with moderate response rates and 
significant prolongation of event free survival. In melanoma IFN-α in combination with 
chemotherapy has shown increased response rates but this has not translated into 
improved overall survival (Jonasch and Haluska, 2001).  
IFN-α has also been used to treat a variety of haematological malignancies including 
chronic myeloid leukaemia (CML), hairy cell leukaemia, acute myeloid leukaemia, 
multiple myeloma and follicular lymphoma. Until the advent of tyrosine kinase inhibitors 
IFN-α formed the mainstay of treatment of patients with CML who were not eligible for a 
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bone marrow transplant. IFN-α treatment resulted in a haematological response rate of 
50-70% and improved progression free and overall survival in patients with CML (1994; 
Allan et al., 1995). IFN-α has also been shown to be highly effective in hairy cell 
leukaemia with response rates of over 80% (Quesada et al., 1984). In the UK Medical 
Research Council AML11 trial low dose IFN-α (3MU thrice weekly) was used as 
maintenance treatment in older patients with AML with no significant benefit in relapse 
risk or overall survival (Goldstone et al., 2001). In myeloma, induction treatment with 
combination chemotherapy (melphalan and prednisolone) and IFN-α was shown to result 
in a significantly improved response rate than with chemotherapy alone (68% versus 42% 
respectively) (Osterborg et al., 1993). Other studies however have failed to demonstrate a 
beneficial effect for IFN-α during induction treatment for myeloma (Gertz et al., 1995; 
Oken et al., 1999). IFN-α has also been used as maintenance treatment in myeloma and 
was shown to improve median duration of response and overall survival in a study by 
Mandelli et al (Mandelli et al., 1990). These results however have not been corroborated 
by other studies (Peest et al., 1995; Salmon et al., 1994). The study by Westin et al 
showed a prolongation of duration of response with IFN-α maintenance treatment but no 
difference in survival (Westin et al., 1995). 
 
1.8.6 Antitumour activity of interferon-β 
The majority of clinical studies in haematological malignancies using type I IFNs have 
been with IFN-α. However there has been an increasing number of preclinical and clinical 
studies evaluating the antitumour effects of IFN-β against a range of solid tumours as 
well as haematological malignancies. In vitro experiments have suggested greater 
antitumour effects for IFN-β compared with IFN-α against melanoma (Johns et al., 1992) 
and glioma (Rosenblum et al., 1990) cell lines. IFN-β was shown to have significant 
antitumour efficacy in xenograft models of Ewings sarcoma (Sanceau and Wietzerbin, 
2004), bladder carcinoma (Izawa et al., 2002), neuroblastoma (Streck et al., 2004) and 
prostate carcinoma (Dong et al., 1999).  In human trials IFN-β has been shown to be 
effective in hairy cell leukaemia with a daily dosing regimen of 2-6 x106 IU/m2 (Liberati 
et al., 1990b; Liberati et al., 1991). Phase II trials with IFN-β in myeloma showed only a 
minimal response with transient stabilisation of disease followed by tumour progression 
once treatment was discontinued (Liberati et al., 1990a). Combination treatment using 
recombinant interleukin-2 (IL-2) and IFN-β proved no more effective than IL-2 alone 
when treating patients with non-Hodgkin’s lymphoma and significant side effects were 
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seen (Duggan et al., 1992).  At the outset of this thesis no other group had evaluated the 
use of  IFN-β in patients with AML.     
 
1.8.7 Limitations in the clinical use of IFNs-α/β     
A major limiting factor in the therapeutic use of IFNs is their toxicity. In many of the 
above mentioned studies there was a significant discontinuation rate due to side-effects of 
fever and flu-like symptoms. Furthermore due to its short half life IFN has to be 
administered atleast three  times a week resulting often in poor compliance. Failure to 
adequately maintain therapeutic levels of IFN in plasma may be a significant limiting 
factor in its efficacy against malignancies. 
 
1.9  Adeno associated virus 
Adeno associated virus vectors (AAV) along with oncoretroviral vectors are among the 
most frequently used viral vectors for gene therapy. The lack of pathogenicity of the 
virus, the persistence of the virus and the availability of multiple serotypes with differing 
tropism have been the main factors facilitating its use as a delivery vector for gene 
therapy. 
 
1.9.1 AAV structure and life cycle 
AAV is a single stranded DNA virus which requires the presence of a helper virus for 
infection. Uniquely amongst viruses, wild type AAV demonstrates site specific 
integration into a region on chromosome 19q13.4 termed AAVS1. The most well 
characterised serotype AAV-2 genome consists of single stranded DNA about 4.7kb in 
length. There are two 145bp inverted terminal repeats (ITRs) flanking two open reading 
frames (ORFs) which contain the REP and CAP genes. The ITR acts as the origin of 
replication and serves as a priming site for second strand synthesis by DNA polymerase. 
They are also essential for AAV genome packaging, transcription and site specific 
integration  The first ORF encodes four REP proteins Rep78, Rep68, Rep52 and Rep40 
which are required for DNA replication, site specific endonuclease and DNA binding 
activity. The second ORF encodes three viral capsid proteins – VP1, VP2 and VP3 with 
molecular weights of 87, 72 and 62 kda respectively (see Figure 1.4). 
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Figure 1.4 Schematic diagram of AAV genome and encoded proteins 
 
AAV-2 gains entry into host cells by binding to the heparin sulphate proteoglycan 
receptor followed by internalisation mediated through interactions with several 
coreceptors including αvβ1 and αvβ5 integrins, fibroblast growth factor receptor 1, 
hepatocyte growth factor and laminin receptor. AAV virions are endocytosed into clathrin 
coated vesicles and traffic to the nucleus where they are released from endosomes and 
undergo uncoating of the viral capsids prior to nuclear entry. Once inside the nucleus 
AAV, in the presence of helper virus, enters a lytic stage with viral genome replication, 
expression and virion production. In the absence of helper virus AAV enters a latent cycle 
and integrates at the AAVS1 locus. 
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Figure 1.5 Schematic diagram showing the life cycle of wild type AAV 
 
1.9.2 AAV as a gene therapy vector 
For the purpose of gene therapy applications recombinant AAV (rAAV) vectors have 
been constructed lacking in REP and the integration efficiency element (IEE) required for 
site specific integration. This ensures that rAAV vectors persist in host cells primarily 
episomally reducing the potential risk of insertional mutangenesis. On the other hand the 
site specific integration capacity of AAV vectors into the potentially safe AAVS1 site is 
now being harnessed by developing mutant vectors that express REP during transduction 
but prevent it from being incorporated. This would enable safe integration and long term 
transgene expression of rAAV into stem cells where cell turnover would otherwise have 
resulted in loss of transgene from episomal AAV in the progeny.  
Most of the early rAAV vectors were based on AAV-2 but these vectors were found to be 
inefficient both in terms of the time required to reach peak expression (several weeks) and 
the level of transgene expression in targeted tissues such as muscle, brain, liver and 
retina. The efficiency of AAV transduction is dependent on each of the steps of AAV 
infection namely AAV binding, cell entry, trafficking to the nucleus, nuclear entry, 
uncoating and second strand synthesis. However the rate limiting factors were found to be 
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inefficient AAV trafficking and second strand synthesis. One strategy adopted to reduce 
the lag time before optimal transgene expression and potentially enhance the level of 
expression was to develop self complementary (scAAV) vectors where the transgene is 
packaged as complementary dimers within a single virion.  scAAV vectors bypass the 
need for second strand synthesis and have been shown to improve the transduction 
efficiency of the liver in mice by at least 20 fold compared with conventional AAV 
vectors (Nathwani et al., 2006). The packaging capacity of a scAAV vector (2.2kb) is half 
that of of ssAAV vectors, however this is still sufficient for a great number of 
applications. 
Atleast 10 different AAV serotypes have now been described with differing capsid 
protein sequences. Although the receptors have been identified for only some of the 
serotypes, what is clear is that the tropism of the serotypes are very different. This 
property has been utilised to pseudotype rAAV vectors with the appropriate capsid 
depending on the intended application. For example AAV-9 serotype was found to 
exhibit greater tropism for the central nervous system when compared to serotypes 1,6 
and 8 (Gray et al., 2011). Similarly both AAV5 and AAV-8 pseudotyped rAAV vectors 
show significant tropism for the liver in non human primates (Nathwani et al., 2007). 
A further potential limitation of rAAV vectors is the host immune response to AAV 
infection. Preexisting neutralising antibodies, because of prior infection, account for the 
humoral response seen towards AAV. Cell mediated responses to AAV have been 
reported and are thought to depend on the route of administration and AAV serotype. 
Selective use of appropriate AAV serotypes (for instance use of AAV-8 which is less 
likely to encounter pre-existing immunity on account of its low seroprevalence) and the 
use of adjuvant immunosuppressants are strategies being developed to mitigate the host 
immune response. 
A number of clinical trials have now been conducted with rAAV vectors with some still 
ongoing. Most of the trials have been for monogenic diseases where the gene product is 
either non functional or absent as in Haemophilia B, cystic fibrosis, Duchene muscular 
dystrophy and Leber congenital amaurosis. However rAAV vectors have also been used 
in other disorders such as Parkinson’s disease, rheumatoid arthritis and prostate cancer. 
The most impressive results so far have been when rAAV was delivered directly into the 
retina to treat Leber’s Congenital Amaurosis (Maguire et al., 2008) and also when used 
intravenously to treat Haemophilia B (Nathwani et al., 2011). 
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1.10 Lentiviral vectors 
HIV derived lentiviral vectors have become increasingly popular in both clinical and non 
clinical research on account of their unique ability to stably transduce both dividing and 
non dividing cells making them one of the most efficient gene delivery vectors. 
Lentiviruses are enveloped RNA viruses from the Retroviridae family of viruses. They 
are composed of 2 copies of RNA, a nuclear capsid, a capsid, a membrane associated 
matrix, envelope proteins such as surface glycoproteins and transmembrane proteins, 
enzymes such as integrase, protease, reverse transcriptase and accessory proteins namely 
Nef, Vif, Vpu, Vpr. The replication cycle of lentiviruses begins by first binding to a host 
cell surface receptor via the surface glycoprotein of the virus. The membranes of the viral 
envelope and the host cell surface membrane then fuse allowing entry of the virus into the 
cell. Following entry, uncoating and reverse transcription takes place leading to the 
formation of a pre-integration complex which can actively enter through the nuclear 
envelope into the nucleus of the infected cell and integrates into the host genome. 
Importantly nuclear entry by the pre-integration complex is not dependent on cell division 
unlike other retroviral vectors. Transcription and translation are followed by assembly of 
structural viral proteins with viral RNA leading to newly formed viral particles which 
escape from the cell by budding and mature outside the cell.  
Lentiviral vectors have undergone sequential improvements to the original HIV based 
construct in order to minimise the risk of accidentally generating a replication competent 
virus and also to increase their packaging capacity as well as to improve their 
transduction efficiency for a wide variety of mammalian cell types. Some of the current  
third generation lentiviral vectors use a 4 plasmid vector system  with the structural gag 
and pol genes, the REV gene and the env gene encoded by separate plasmids with the 
packaging sequence (ψ) deleted from these plasmids. Furthermore the HIV accessory 
proteins such as tat, vpr, vrf and nef have all been deleted. The fourth plasmid with an 
intact ψ sequence encodes the transgene of interest. By splitting the vector system into 4 
plasmids, the number of recombination events between the plasmids required to generate 
a replication competent virus is extremely high and to date there have been no reported 
cases of such an event occurring.   
Other modifications made to the lentiviral vector include a deletion in the U3 region of 
the 3’ LTR making the LTR effectively inactive, the use of heterologous sequences such 
as the vesicular stomatitis virus envelope gene to replace the native HIV envelope which 
enhances safety as well as to broaden tropism and replacement of the U3 region of the 5’ 
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LTR with other promoter sequences to drive tat-independent transcription. The addition 
of the woodchuck hepatitis virus post transcriptional regulatory element (WPRE) has 
been shown to stabilise transgene mRNA levels and thereby enhance transgene 
expression. Insulator elements such as the chicken β-globin locus HS4 element have also 
been used to separate transgene expression from regions of the chromosome that surround 
the site of vector integration thereby reducing the potential genotoxic risks of vector 
insertion. 
 
 
Figure 1.6 Schematic diagram showing the four plasmid lentiviral vector system 
 
 
 
 
 
Figure 1.7 Basic structure of a third generation self inactivating lentiviral vector. 
CA, capsid; CTS, central termination site; LTR, long terminal repeat; PPT, polypurine 
tract; Ψ, packaging sequence; WPRE: woodchuck hepatitis B posttranscriptional element. 
 
Onco-retroviral vectors have now been shown to cause insertional mutagenesis not only 
in mouse models but also in patients with X-linked severe combined immunodeficiency 
who were transplanted with haematopoietic stem cells transduced with a murine 
oncoretroviral vector expressing the common γ-chain of the interleukin-2 receptor 
(Cavazzana-Calva., et al 2000; Howe., et al 2008), some of whom developed leukaemia. 
In these patients it was shown that the retroviral vector integrated in proximity to the 
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LMO2 proto-oncogene promoter resulting in aberrant expression of the LMO2 gene and 
subsequent uncontrolled cell proliferation.  Enhancer elements within the oncoretroviral 
LTR were thought to responsible for perturbation of the LMO2 gene. Lentiviral vectors 
were shown to be less genotoxic compared with oncoretroviral vectors in a Cdkn2a-/- 
mouse transplantation model which is susceptible to a broad range of cancer triggering 
genetic lesions (Montini., et al 2006). Furthermore there have been no oncogenic events 
observed in clinical trials using lentiviral vectors to date although clonal expansion and 
dominance of haematopoietic progenitors has been reported in a gene therapy trial of 
thalassaemia using haematopoietic cells transduced with a lentiviral vector expressing the 
β-globin gene (Cavazzana-Calvo., et al 2010). 
A number of clinical trials utilising lentiviral vectors are now underway for indications 
such as X-SCID, ADA-SCID and Wiskott-Aldrich syndrome where haematopoietic stem 
cells are being transduced, HIV infection and B-cell NHL where T cells are the target cell 
ex vivo as well as conditions such as Stargardt’s Macular degeneration and Retinitis 
pigmentosa where the vector is directly administered to the retina of patients. 
 
1.11 Summary and Aims 
Angiogenesis plays a key role in the pathogenesis of haematological malignancies such as 
acute myeloid leukaemia, multiple myeloma and lymphoma. The evidence supporting this 
hypothesis includes the finding of increased bone marrow microvessel density and  
increased levels of plasma and urinary pro-angiogenic cytokines in patients with these 
malignancies as well as the encouraging results from preclinical and clinical studies using 
antiangiogenic therapies. The common limiting factor in most of these studies has been 
the short half-life of many of the antiangiogenic compounds. The pharmacokinetics of 
these antiangiogenic molecules has necessitated the use of cumbersome administration 
protocols with significant side effects seen in association with peak levels. This has 
resulted in poor compliance and an inability to administer the drug long enough to result 
in its desired therapeutic effect.  
Interferons are a group of cytokines with significant antitumour activity as a result of their 
anti-proliferative, anti-apoptotic and anti-angiogenic effects. Interferon-α has been shown 
to have some anti-leukaemic and anti-myeloma activity but again its short half-life has 
limited its therapeutic potential. Previous work has demonstrated more potent antitumour 
responses to IFN-β than IFN-α. The effects of IFN-β on AML however have not 
previously been studied in any systematic fashion.   
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The aim of this thesis is to investigate the therapeutic effects of stable antiangiogenic 
expression in xenograft models of AML, lymphoma and myeloma. More specifically the 
antitumour effects of blocking the vascular endothelial growth factor (VEGF) pathway 
and the matrix metalloproteinase pathway will be investigated by stably expressing either 
the soluble VEGFR-2 receptor (sFLK-1) or TIMP-3 using viral vectors. In addition we 
will also evaluate the effects of sustained systemic expression of hIFN-β in xenograft 
models of AML using AAV vectors. Furthermore the mechanisms of action of IFN-β will 
be investigated and its anti-tumour efficacy compared with the more commonly used 
cytokine IFN-α. 
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2.1 Cell culture 
All cell lines were obtained from ATCC (www.ATCC.org). 
 
2.1.1 Adherent cell lines 
Human embryonic kidney transformed 293T cells and HeLa cervical carcinoma cells 
were cultured in 20cm2 tissue culture plates in Dulbecco’s Eagle’s Medium (DMEM-Life 
Technologies) with 10% heat inactivated fetal calf serum and 1% penicillin, streptomycin 
and amphotericin (D10) at 37°C and 5% CO2. Cultures were split by trypsinisation when 
cells approached confluence every 2-3 days. This was done by washing cells gently with 
PBS lacking Ca2+ or Mg2+  and then adding 3mls of warm 1x Trypsin/EDTA which 
results in detachment of cells within 2-5 minutes. D10 medium was added to terminate 
the trypsin reaction and cells were then split 1:5 into fresh tissue culture plates.  
 
2.1.2 Suspension cell lines 
The AML cell lines HL-60, KG-1α, AML193 and OCI AML5 were cultured in 80cm2 
tissue culture flasks in RPMI 1640 medium (Life Technologies) with 10% heat 
inactivated fetal calf serum (FCS) and 1% penicillin, streptomycin and amphotericin 
(R10) at 37°C and 5% CO2. GMCSF at 100pg/ml was added to the medium for AML193 
and OCI AML5 cells. Cells were maintained at a density of 1x106/ml by splitting the 
culture 1:10 every 2-3 days with fresh medium. The myeloma cell lines ARH77 and 
KMSBM as well as the lymphoma cell lines Raji and U937 were also cultured in a similar 
way without any growth factor supplements.  
 
2.1.3 Primary leukaemia cells 
Primary leukaemia cells (blasts) were obtained from patients with relapsed AML under 
the care of University College London Hospitals NHS Trust, in accordance with local 
ethical guidelines and with LREC approval. When clinically indicated, patients with high 
peripheral blast counts were subjected to a standard apheresis procedure and the 
leukaemia cells subsequently separated by Ficoll gradient centrifugation. Mononuclear 
cells (>90% of which were blasts) were frozen in liquid nitrogen in RPMI medium with 
50% FCS and 10% dimethyl sulphoxide. Once thawed cells were cultured in RPMI 
medium with 10% FCS in the absence of cytokines. 
 
2.2  Microscopy and Immunostaining 
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2.2.1 Routine microscopy 
Cytospin preparations and blood smears were visualised following May-Grunwald-
Giemsa staining with an Olympus IX70 inverted microscope. Cell counts and viability 
assessments were made using trypan blue exclusion and a haemocytometer. 
 
2.2.2 Flow cytometry 
An EPICS Elite flow cytometer (Beckman-Coulter) was used for both Fluoresence-
activated cell sorting (FACS) analysis and cell sorting. Usually 0.5-1.0 x106 cells were 
stained with 5µl of the appropriate FITC, PE or APC conjugated antibody (human CD45, 
CD13 or CD138 – all from BD Biosciences) for 20 minutes at room temperature. Cells 
were then washed twice with FACS buffer (PBS with 2% FCS) and suspended in 400µl 
of either FACS buffer or fixative (1% paraformaldehyde). Samples were run on the flow 
cytometer and both percentage fluorescence and mean cell fluorescence was measured. A 
minimum of 10000 events was usually collected for each sample. Cell sorting was usually 
done with GFP by setting gates around the top 25% mean GFP +ve population using 
standard methods. 
 
2.2.3 Immunohistochemistry 
Organs harvested from sacrificed mice were promptly fixed in 10% formaldehyde/saline 
for atleast 24 hours. Bone tissue was subsequently decalcified in 10% formic acid for 48-
72 hours. Fixed/decalcified tissue was then paraffin embedded and 3 µm tissue sections 
cut for immunohistochemical studies and mounted on Capillary Gap Microscope slides 
(Dako Ltd., High Wycombe, Berks, UK). Prior to immunostaining tissue sections were 
put through a heat mediated antigen retrieval step by placing them in a pressure cooker 
for 2 minutes at full pressure in 3 L of citrate buffer (pH 6.0). Sections were then stained 
with a primary monoclonal anti-human CD45RB antibody (Dako M0833, 1:100 dilution) 
for 2 hours after blocking with a mouse immunoglobulin blocking reagent (Vector labs 
PK-2200) for one hour. Slides were then incubated with a biotinylated goat anti-mouse 
antibody, stained with Streptavidin Peroxidase before final addition of a chromogenic 
substrate (Dako ChemMate Detection kit K5001). 
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2.3  Cell proliferation/apoptosis/viability assays 
2.3.1 Tritiated thymidine assay 
Tumour cell lines were seeded in 96 well plates at 20,000 cells per well in 200µl of RPMI 
with 10% FCS to which varying concentrations of recombinant human IFNβ-1a (Avonex) 
or IFNα-2b (Intron A) were added. Following stimulation for 48-72 hours, cells were 
pulsed with 3H-thymidine (0.5µC per well) for 4 hours, harvested and 3H-thymidine 
incorporation measured by scintillation counting.  
 
2.3.2 MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium) assay 
Tumour cell lines were seeded in 96 well plates at 20,000 cells per well in 200µl of RPMI 
with 10% FCS to which varying concentrations of recombinant human IFNβ-1a 
(Avonex), IFNα-2b (Intron A) or cytarabine were added. Cells were incubated for 48-72 
hours following which MTS activity was measured by the CellTiter kit (Promega, 
Southampton, UK) according to manufacturer’s instructions.  
 
2.3.3 Annexin V viability assay 
To determine the proportion of apoptotic cells following exposure to interferons after 48-
72 hours incubation, cells were pelleted at 350g for 5 minutes and then washed once in 
Annexin V binding buffer (140mM NaCl, 10mM HEPES pH 7.4 and 5mM CaCl2) before 
incubation for 10 minutes on ice with 1µl Annexin V-FLUOS (Roche) in 50µl annexin V 
binding buffer to which 1µl of propidium iodide (50µg/ml) was added. Specific 
fluorescence was then determined using an EPICS Elite flow cytometer. Apoptotic cells 
were calculated as the proportion of cells that were Annexin V positive and Propidium 
iodide negative. 
 
2.3.4 Cell cycle analysis 
Following stimulation with interferons for 72 hours, tumour cells were pelleted by 
centrifugation and then resuspended in 1ml 70% methanol in PBS at -20°C. After a 
minimum of 30 minutes fixation, the cells were pelleted once more, washed once in PBS 
and then incubated for 30 minutes in staining solution (200µl propidium iodide stock 
solution and 500µl RNAase stock solution to 10mls in PBS with Ca2+ and Mg2+) at 37°C. 
Samples were then analysed by flow cytometry. 
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2.3.5 TUNEL (TdT-mediated dUTP Nick End labeling) assay 
The TUNEL assay was used to demonstrate apoptotic cells in tumours extracted from 
mice treated with hIFNβ. Frozen sections from subcutaneously implanted HL-60 tumors 
as well as formalin fixed paraffin embedded tissue sections from intravenously injected 
HL-60 leukemic mice were used for TUNEL staining. Frozen sections were fixed in 4% 
paraformaldehyde, rehydrated in PBS and permeabilised in 1% Triton-X-100, 0.1% 
Sodium citrate. Paraffin sections were dewaxed, rehydrated and proteinase K treated prior 
to permeabilisation. A fluorescein TUNEL labeling kit (Roche Cat No 11684795001) was 
then used to label apoptotic cells followed by counterstaining with DAPI. Slides were 
analysed by fluorescence microscopy.  
 
2.4 Protein assays 
2.4.1 Western Blotting 
2.4.1.1 Cell lysates 
Total cell lysates were made by pelleting 5x106 cells by centrifugation and resuspending 
them in 50µl of ice cold RIPA buffer (Sigma) containing protease inhibitors (Complete 
protease inhibitor tablets, Roche) for 10 minutes on ice. The lysates were spun again at 
20,000g for 10 minutes and the clear supernatants removed. The appropriate volume of 
4x sample buffer was added to the supernatants and the lysates boiled in a 100°C hot 
block for 5 minutes. 
 
Sample Buffer (4x) : 320nM Tris pH 6.8 
   8% SDS 
   4.6% DTT 
   40% Glycerol 
   1mg/ml bromophenol blue 
 
2.4.1.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Depending on the size of the protein of interest 10% or 15% polyacrylamide gels were 
prepared. Lysates were loaded into the gels and electrophoresis was performed in Mighty 
Small Electrophoresis Units (Amersham) by applying a 200V charge across the gel for 2 
hours. A prestained protein ladder (Invitrogen) was run for each gel. 
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Polyacrylamide running gel (10mls - sufficient for 2 gel plates) 
 10% 15% 
Distilled water 2.9mls 1.2mls 
1M Tris pH 8.8 3.7mls 3.7mls 
30% acrylamide 3.3mls 5.0mls 
10% SDS 100µl 100µl 
10% ammonium persulphate 75µl 75µl 
Temed 9µl 9µl 
 
 
Polyacrylamide stacking gel (5mls – sufficient for 2 gel plates) 
Distilled water 3.5mls 
1M Tris pH 6.8 0.63mls 
30% acrylamide 0.84mls 
10% SDS 50µl 
10% APS 38µl 
Temed 7.5µl 
 
Gel running buffer (10x) :  Tris 30g (250mM) 
    Glycine 144g (2M)     
    SDS 10g (1%) 
    Distilled water to 1L 
 
2.4.1.3 Transfer of proteins on to nitrocellulose membrane 
Following electrophoresis the gels were removed from the glass plates and transferred 
onto a pre wet nitrocellulose membrane (Hybond C extra, Amersham) using a semi dry 
transfer apparatus (NBS Biologicals) as per manufacturer’s instructions. 
 
Gel transfer buffer (10x) : Tris 30g (250mM) 
    Glycine 144g (2M) 
    Distilled water to 1L 
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2.4.1.4 Incubation of nitrocellulose membranes with antibodies 
After transfer of proteins onto nitrocellulose membranes they were blocked with 1% 
skimmed milk (Marvel, Premier Brands) in PBS overnight at 4°C. They were then 
incubated  with primary antibodies  at 1 in 1000 dilution in PBS with 3% bovine serum 
albumin (BSA) for 2 hours at room temperature. The membranes were washed 3 times 
with PBS containing 0.1% Tween (PBST) and then incubated with the appropriate 
secondary horseradish peroxidise conjugated anti-mouse, anti-goat or anti-rabbit 
(Amersham Pharmacia) antibody at a dilution of 1:10000 in PBS with 3% BSA. After a 
further 3 washes in PBST, protein bands were visualised by chemiluminescence (ECL or 
ECL plus, Amersham Pharmacia). 
  
Primary Antibodies :  
Rabbit antihuman Timp-3   (Chemicon International) 
Goat antimouse VEGFR2 (Flk-1)  (R&D Systems) 
Rabbit Phospho-Stat1(Ser727)  (Cell Signalling Technology) 
Rabbit Phospha-Jak1(Tyr1022/1023) (Cell Signalling Technology) 
Mouse anti-β tubulin   (Chemicon International) 
 
2.4.2 Enzyme-linked immunosorbent assay (ELISA) 
2.4.2.1 sFlk-1 ELISA 
A 96 well ELISA plate (Nunc) was coated with 100 µl of anti sFlk-1 antibody (R&D 
Systems AF644) at 1 in 40 dilution in coating buffer (0.1M NaHCO3 pH 10.6) and 
incubated overnight at 4°C. The next day the plate  was washed five times with 200 µl 
phosphate buffered saline  Containing 0.1% Tween-20 (PBST). A blocking step was then 
performed with 100 µl of blocking buffer (PBST with 2% BSA) added to each well and 
incubated for one hour at room temperature. The plate was washed again five times as 
before followed by addition of 100 µl of the sFlk-1 standards (recombinant mouse 
VEGFR-2, R&D Systems 443-KD) and serum samples at 1 in 500 dilution for one hour at 
room temperature. After a further 5 washes the plate was incubated for one hour at room 
temperature with 100 µl of biotinylated anti sFlk-1 antibody (R&D Systems BAF644) 
diluted at 1 in 50 in blocking buffer. The plate was washed again and 100 µl of antibiotin 
peroxidase (Sigma A0185) added at 1 in 30000 dilution for one hour at room temperature 
followed by 100 µl of peroxidase substrate (Sigma P9187). The reaction was stopped at 
15 minutes with 100µl of 3M HCL and optical density of each standard/sample measured 
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using an Anthos 2001 ELISA plate reader at a wavelength of 492 nm. sFlk-1 
concentration of each sample was then calculated from the standard curve generated. 
 
2.4.2.2 VEGF antibody ELISA 
ELISA was performed as above with recombinant human VEGF (R&D Systems 293-VE) 
used to coat the plates at a concentration of 100ng/ml in coating buffer. Following the 
blocking step and then addition of samples/standards, peroxidise conjugated anti human 
IgG Fc (Sigma) was added. Optical density was measured as before after addition of the 
peroxidise substrate and termination of the reaction with 3M HCL. 
 
2.4.2.3 M-protein (human immunoglobulin IgG) ELISA 
ELISA plates were coated with 100 µl of anti-human IgG (Biosource AH10301) at 
1µg/ml in 0.1M NaHCO3 pH 10.6 overnight at 4°C. The following day plates were 
washed five times with PBST and blocked with 100µl per well of PBST with 2% BSA for 
one hour at room temperature. The plates were washed again and 100µl of hIgG standards 
(ICN/cappel) and serum samples were added to the wells for 2 hours at room temperature. 
After washing 5 times 100µl of alkaline phosphatase (ALP) conjugated goat anti-human 
IgG (Biosource AH10305) was added to each well and incubated for 2 hours at room 
temperature. The plate was washed again as before and 100µl of ALP substrate (Sigma) 
was added for one hour at room temperature. Once colour change of the reaction was 
obvious (usually at 15 minutes), optical density was measured at a wavelength of 405nm. 
Concentration of hIgG in the serum samples was calculated from the standard curve. 
 
2.4.2.4 Human VEGF ELISA 
Human and murine VEGF were quantified using the R&D Systems Quantikine ELISA 
kits (Catalog Numbers DVE00 and MMV00 respectively) as per manufacturer’s 
instructions.  
 
2.4.3 Interferon-α/β antiviral assay 
A functional antiviral assay was used to quantitate the amount of hIFNα/β in the serum of 
mice either transduced with AAV-hIFNα/β or injected with recombinant IFN. This assay 
measures the ability of IFN in test samples to prevent lysis of a glioblastoma cell line 
(2D9) by the encephalomyocarditis virus (ECMV) (Meager, 2004). Briefly 2D9 cells 
were seeded in a microtiter plate at 50000 cells per well and incubated overnight at 37°C. 
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Mouse serum samples at varying dilutions as well as recombinant IFN controls were 
added to the wells the following day and left for 24 hours at 37°C. The next day the plate 
was washed and ECMV virus was added to the wells and incubated at 37°C for 24 hours. 
The following day the plate was washed and Naphthol blue black substrate added 
followed by 0.1M NaOH, prior to measurement of absorbance at 610nm using an ELISA 
plate reader. 
 
2.5 Molecular Biology 
2.5.1 General DNA methods 
2.5.1.1 DNA agarose gel electrophoresis 
A 1% agarose gel was made by dissolving either standard agarose (GibcoBRL)  or low 
melting point (LMP) agarose in 1 x TAE buffer in a microwave oven. 1µl of ethidium 
bromide was added before the gel was poured into the electrophoresis tank (Horizon 58 – 
Life Technologies) with the lane comb in place. Once the gel was set the tank was filled 
with 1 x TAE buffer and the wells loaded with DNA samples (9µl of sample with 1µl of 
10x loading buffer). A DNA fragment ladder was added to one of the wells to determine 
the size of the resolved fragments. The gel was run approximately at 50V for 1 hour. 
Resolved fragments were visualised using an ultraviolet box and photographed using a 
Polaroid camera. 
 
10 x TAE buffer (Tris/Acetic acid/EDTA) :  28.4g Tris 
      11.42 mls acetic acid 
      20 mls 0.5M EDTA pH 8.0 
      Distilled water to 1L 
 
2.5.1.2 DNA fragment gel purification 
PCR products or DNA fragments digested with restriction endonucleases were run on 
LMP gels, visualised on an ultraviolet box and the desired band cut from the gel using a 
scalpel blade. The gel fragment was then purified using a commercially available kit 
(QIAquick gel extraction kit, Qiagen) as per manufacturer’s instructions. 
 
2.5.1.3 Restriction endonuclease digests 
Restriction digests of plasmids were done either to release fragments of interest for 
subsequent cloning or to check the orientation of ligated fragments. Typically 5-10µl of 
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plasmid (1µg/µl) was digested with 1µl of restriction enzyme, 1µl of bovine serum 
albumin (100µg/ml) and 3µl of the appropriate 10x endonuclease buffer in a total reaction 
volume of 30µl made up with distilled water. Digests were performed for one hour at 
37C. 
 
2.5.1.4 Ligation of restriction endonuclease digested fragments 
Digested plasmids were first treated with alkaline phosphatase (Roche, 1µl of 10mg/ml 
solution for 5 minutes at 37C), where necessary, to minimise self annealing. Ligation of 
digested fragments was performed with 1µl T4 DNA ligase (Roche), 1µl 10x buffer, 1µl 
vector fragment and 1-5µl of insert fragment (vector : insert DNA molar ratio of 1:3) in a 
total reaction volume of 10µl with distilled water. Ligation was done at 16C overnight 
followed by transformation of the ligated plasmids into competent bacteria. 
 
2.5.1.5 Transformation of competent bacterial cells 
DH5α Escherichia coli competent cells were transformed by carefully adding 5-10µl of 
ligation reaction to 100µl cells and incubating on ice for 30 minutes. Cells were then heat 
shocked for 45 seconds at 42C and returned to ice for 2 minutes. 250µl of S.O.C medium 
was added to the cells which were then placed in an orbital shaker at 37C for 1 hour. 
Cells were then streaked on ampicillin containing agar plates for overnight culture at 37C. 
The following day colonies were picked for screening. 
 
2.5.1.6 Plasmid preparation techniques 
Mini-preps : These were done to provide small amounts of DNA sufficient for checking 
the orientation of cloned fragments by restriction digestion, generating a fragment for 
subsequent cloning or DNA sequence analysis. Bacterial colonies were picked from agar 
plates with sterile pipette tips and placed into 3mls of LB containing 50µg/ml of 
ampicillin in a sterile Falcon tube for overnight culture at 37C in an orbital shaker. The 
next day mini-preps were performed using a commercial kit (QIAprep spin miniprep kit, 
Qiagen) as per manufacturer’s instructions. 
 
Mega-preps : These were done to generate large amounts of DNA (upto 2.5mg) for 
transfection purposes. 1ml of LB culture containing bacterial cells transformed with the 
desired plasmid was inoculated into 500mls of LB containing 50µg/ml of ampicillin in a 
4L conical flask and incubated overnight at 37C in an orbital shaker. Maxi-preps were 
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then done using a commercial kit (QIAGEN Plasmid Mega kit, Qiagen) as per 
manufacturer’s instructions. 
 
2.5.2 RT-PCR / PCR 
RNA was extracted from IFN treated cell lines using Trizol (Invitrogen) as per 
manufacturer’s instructions. Reverse transcriptase reaction was performed with 1µg of 
RNA using reagents from Promega (A5000) as per manufacturer’s protocol in a 20µL 
reaction. 2µl of cDNA was then used in a 20 µl PCR reaction. Primers (from Invitrogen) 
directed against human VEGF, bFGF, MMP-2 and MMP-9 were used in separate PCR 
reactions, again using reagents from Promega (C1141). PCR was also done to amplify 
human FIX in DNA samples extracted from murine tissue. GAPDH or murine β-actin 
was used as a control gene for human tumour cell lines or murine tissue respectively. 
Annealing temperatures of 59°C were generally used with 30 cycles of amplification. 
 
Primer sequences (5’-3’) 
VEGF  F: TCGGGCCTCCGAAACCATGA   
VEGF   R: CCTGGTGAGAGATCTGGTTC 
MMP-2 F: GGCCCTGTCACTCCTGAGAT 
MMP-2 R: GGCATCCAGGTTATCGGGGA 
MMP-9 F: CAACATCACCTATTGGATCC 
MMP-9 R: CGGGTGTAGAGTCTCTCGCT 
hFIX  F: GATCATGGCAGAATCACCAG 
hFIX  R: GCATCTTCTCCACCAACAAC 
mβ-actin F: TGACGGGGTCACCCACACTGTGCCCATCTA 
mβ-actin R: CTAGAAGCATTTGCGGTGGACGATGGAGGG 
GAPDH F: CCC CAC ACA CAT GCA CTT ACC 
GAPDH R: CCT ACT CCC AGG GCT TTG ATT 
 
2.5.3 Southern Blotting 
DNA digest : 10µg of genomic DNA samples along with a negative control and negative 
DNA spiked with dilutions of standards was digested with 50 Units of restriction enzyme 
in a 70µl total reaction volume for 6 hours. Following digestion 10µl of 6x loading dye 
was added and 70µl of the mixture was loaded on a 0.8% agarose gel in 1x TBE. 
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Electrophoresis was carried out at 60-90V for 5-6 hours or until the orange marker dye 
reaches the bottom of the gel. 
 
Denaturation of gel : The gel was stained with 10µl of 100mg/ml ethidium bromide for 10 
minutes and an image of the bands was taken on an ultraviolet box. Depurination of the 
gel was carried out with 0.1M HCl for 30 minutes. After rinsing, the gel was denatured 
twice for 15 minutes in 0.5M NaOH on a shaker. 
 
Transfer on to membrane : Denatured gel was transferred onto a nitrocellulose membrane 
using the TURBOBLOTTER system (Schleicher & Schuell) as per manufacturer’s 
instructions. 
 
Preparation of probe : The green fluoresecent protein (GFP) gene located in the lentiviral 
vector plasmids MSCV-Flk-1-ires-GFP, MSCV-Timp-3-ires-GFP or MSCV-ires-GFP 
was used as a probe. A 778bp GFP fragment was isolated from the pCAGG MCS-EGFP 
plasmid by EcoR1 and Not1 restriction digestion and dissolved in Tris-EDTA buffer at a 
concentration such that 25-30ng can be added to the reaction in a volume of no more than 
34µl. The DNA probe was denatured at 95°C for 3 minutes and immediately then put on 
ice. Radiolabelling of the probe was carried out using a commercial kit (NEBlot Kit, New 
England BioLabs) and α-32P dCTP as per manufacturer’s instructions. 
 
Hybridisation of membrane : The membrane, post transfer, was prewet in 2x SSC, dried 
on blotting paper and then crosslinked using ultraviolet light. Pre-hybridisation of the 
membrane was carried out with 10ml of pre-warmed hybridisation buffer (Amersham) at 
42°C for atleast one hour. The radiolabelled probe was diluted in 10mls of hybridisation 
buffer and this was used to replace the prehybridisation buffer. The membrane was 
incubated with the probe overnight at 42°C. 
 
Washing and Imaging : The following day the membrane was washed twice with 500ml 
of wash solution1 for 20 minutes at 65°C followed by twice with wash solution 2 again 
for 20 minutes at 65°C. 
 
 
 
57 
 
Wash solution 1 : 20x SSC 
   10% SDS 50ml 
   Distilled water 850ml 
 
Wash solution 2 : 20x SSC 
   10% SDS 50ml 
   Distilled water 925ml 
    
2.5.4 Slot Blot analysis 
Preparation of sample : 50µl of purified AAV vector was DNase I treated (to remove free 
plasmids from prep) in a 200µl reaction with the appropriate buffer and sterile water at 
37°C for 1 hour. DNase I was inactivated by incubating sample with 2µl of 0.5M EDTA 
at 70°C for 30 minutes.  The sample was then mixed with 2µl of 10% SDS, 4µl of 
10mg/ml Proteinase K, 1µl of 10mg/ml glycogen and incubated at 37°C for 2 hours. This 
step should break down the AAV particles and release the genome. Following this a 
standard phenol/chloroform DNA extraction and ethanol precipitation method was used 
with the final DNA pellet dissolved in 200µl AAV denaturing buffer. Simultaneously the 
AAV DNA standards were prepared by adding 190µl denaturing buffer to 10µl of each 
thawed standard. Denatured samples and standards were then transferred onto a nylon 
membrane through a slot blot apparatus. 
 
Preparation of probe : DNA probes against human FIX or human IFNβ were made 
depending on which AAV vector prep was being quantitated. 25ng of template DNA was 
denatured at 95°C for 5 minutes and radioactively labelled with 32P dCTP using the 
NEBlot kit (New England Biolabs N1500L) as per manufacturer’s instructions. The 
radiolabelled probe (final reaction volume 100µl in TE buffer) was purified using NICK 
spin columns (GE Healthcare). 50µl salmon sperm DNA was added to the purified probe 
followed by incubation with 300µl of 0.4M NaOH at room temperature for 15 minutes. 
The reaction was neutralised with 0.4M HCL before proceeding to the hybridisation step. 
Membrane transfer : The denatured samples and standards (200µl per sample) were 
transferred onto Hybond N+ membrane (GE Healthcare), prewet in 2xSSC buffer 
(20xSSC buffer, Sigma) using the Millipore slot blot apparatus as per manufacturer’s 
instructions. Following DNA transfer the membrane was crosslinked under ultraviolet 
light for 5 minutes. 
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Hybridisation : The transferred membrane was initially prehybridised for one hour with 
10ml of hybrisation solution (Ambion) prewarmed to 42°C. Following this the 
prehybridisation solution was replaced with 10mls of fresh hybridisation solution and the 
radiolabelled probe was added to this and incubated overnight at 42°C in a hybridisation 
incubator.   
 
Membrane washing and imaging : The following day the membrane was washed twice 
with 500mls of wash solution I for 20 minutes in an incubation shaker at 65°C at 65rpm. 
This was followed by a further two washes with 500ml of wash solution II again for 20 
minutes. The membrane was sealed in Saran Wrap before exposure to a phosphoimager 
(Typhoon FLA 9000, GE Healthcare). The titres of the vector preps were calculated from 
the standard curve generated. 
 
Wash Solution I 20x SSC 100ml 
   10% SDS 50 ml 
   Water  850ml 
Wash Solution II 20x SSC 25ml 
   10% SDS 50ml 
   Water  925ml 
 
2.6 Manufacture of viral vectors 
2.6.1 Lentiviral vector production 
A four plasmid calcium/phosphate transient transfection method was used to generate 
lentivirus from 293T cells. 3x106 293T cells were seeded on 10cm2 tissue culture plates in 
DMEM medium with 10% fetal calf serum and 1% penicillin, streptomycin and 
amphotericin (D10). A transfection mixture was made up in water to a final volume of 
500µl per plate with the following plasmids at the given concentration and 50 µl of 2.5 
mM calcium. 
pCL10.1 MSCV-Flk-1-ires-GFP or pCL10.1 MSCV-ires-GFP or pCL10.1 MSCV-Timp-
3-GFP  (Vector plasmids)  10µg per plate 
pKGP3R  (Packaging plasmid)  10µg per plate 
pRTR2  (Helper plasmid)  2.5µg per plate 
pCAGG VSVG (Envelope plasmid)  2.0µg per plate 
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500µl of 2xHepes Buffer was added to the transfection mixture dropwise whilst vortexing 
followed immediately by 9ml of warm D10 medium. All volumes were multiplied by the 
number of plates being transfected. 10 mls of the final transfection mixture was added to 
each plate having aspirated out the old medium. Transfected cells were incubated at 37°C 
and 5% CO2 for 16-18 hours and then observed under ultraviolet light for green 
fluorescence. Plates were then carefully washed twice with PBS and fresh D10 medium 
added. The following day medium containing virus was harvested from each plate, 
centrifuged at 1500 rpm (400G) for 5 minutes, filtered through a 0.2 micron sterile filter 
and subsequently stored in small aliquots at -70°C. 
 
2.6.2 Lentiviral vector concentration 
Lentiviral vector supernatants were concentrated by ultracentrifugation using a Beckmann 
ultracentrifuge. Virus was aliquoted into 30ml sterile Beckmann centrifuge tubes, sealed 
and centrifuged at 27000rpm (77000G) for 90 minutes in a prechilled rotor at 4°C. 
Following centrifugation the supernatants were discarded and the viral pellets 
resuspended in 300 µl of serum free medium (X-vivo 10, BioWhittaker). Concentrated 
virus was then stored at -70°C. 
 
2.6.3 Lentiviral vector titration 
Titration of lentiviral vector preps was performed by assessing their infectivity on HeLa 
cells. 50000 Hela cells per well were seeded into a 6 well plate the day before 
transduction. The following day medium from each well was replaced by 2 mls of a 
transduction mixture containing varying amounts of viral supernatant (ranging from 10µl 
to 1000µl) and corresponding volumes of fresh D10 medium as well as 4µg/ml of 
polybrene. After 48 hours HeLa cells were harvested following the addition of trypsin and 
subsequent inactivation with D10 medium. Cells were pelleted in FACS tubes, fixed in 
0.5% paraformaldehyde and FACS analysis performed to determine the number of cells 
expressing GFP. The titre of each viral prep was calculated based on the number of GFP 
positive cells and the volume of lentiviral prep used assuming that one viral particle was 
required to transduce one cell. 
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2.6.4 AAV vector production - rAAV2, rAAV5 and rAAV8  
Subconfluent 293T cells plated on 15-cm plates were cotransfected with either hFIX, 
hIFNβ or sFlk-1 vector plasmids, a helper plasmid encoding the adenoviral helper genes 
(XX6) necessary for AAV production and packaging plasmids XX2, chimeric AAV2 
Rep-5cap or AAV2 Rep-8cap to generate rAAV2, rAAV5 or rAAV8 pseudotyped vector 
particles respectively using the calcium phosphate method. Cells were harvested between 
50 to 60 hours after transfection and lysed in 1x TD buffer by freeze thawing. The crude 
lysate was then treated with 0.5% deoxycholate (Fisher Scientific) and 50 U/mL 
Benzonase (Sigma), for 30 minutes at 37°C followed by centrifugation at 6000g for 
20minutes. The supernatants were filtered through a 0.45micron filter before proceeding 
to the purification step. rAAV-2 and -5 vectors were purified by heparin and mucin 
affinity chromotography respectively as previously described (Auricchio et al., 2001; 
Clark et al., 1999). rAAV-8 vectors were purified by ion exchange column 
chromatography using a method developed in house (Davidoff et al., 2004). Standard 
slot-blot analysis was used to determine the vector particle titer. 
 
Transfection mixture (for 40 15cm plates) 
Vector plasmid (pAV FIX/hIFNβ/sFlk-1) 600µg 
Helper plasmid (XX6)   1800µg 
Packaging plasmid (XX2 or 2/5 or 2/8) 600µg 
2.5M Calcium     5mls 
2xHBS buffer     50mls 
Water      make up to 50mls 
Neutralise transfection reaction with 100mls DMEM medium with 10% FCS and then 
add 5mls per plate 
 
 
1x TD buffer NaCL   140mM 
  KCL  5mM 
  K2HPO4 0.7mM 
  MgCl2  3.5mM 
  Tris  25mM 
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2.7 Animal studies 
All animal studies were performed in accordance with the Animals Scientific Procedures 
Act (1986) and under the authority of the UK Home Office Project and Personal 
Licences. B6 SCID and β2mnull NOD/SCID mice were purchased from Charles Rivers 
Laboratory, UK and were housed under positive pressure in individually ventilated cages 
(Tecniplast, Northamptonshire, UK). 
 
2.7.1 Collection of mouse plasma/serum 
Prewarmed mice were bled from their tail vein by making an incision with a sterile 
scalpel blade and collecting upto 200µl of blood into either a 1.5ml eppendorf tube (for 
serum) or an EDTA containing paediatric blood tube (for plasma). No more than 10% of 
blood volume was collected every two weeks as per institutional guidelines. Collected 
blood samples were then spun at 8000rpm (5000G) for 15mts in a microcentrifuge and 
the clear supernatants (plasma or serum) harvested and frozen at -20°C. 
 
2.7.2 Tail vein injections 
A 30G needle (BD, Oxford, UK) was used to inject tumour cells or AAV virus or 
recombinant hIFN-β into the tail veins of prewarmed mice. A maximum volume of 300µl 
was injected each time making sure the inoculate was at room temperature prior to 
injection. 
 
2.7.3 Intraperitoneal injections 
The intraperitoneal route was used to inject recombinant hIFN-β  or VEGF antibody or 
anti-RhD antibody. A maximum volume of 300µl was admistered using a 30G needle. 
 
2.7.4 Subcutaneous injections 
The subcutaneous route was used for administration of tumour cells to create orthotopic 
tumour models. HL-60 tumour cells were resuspended in up to 250µl of RPMI with 
10%FCS and implanted subcutaneously in the flank regions using a 30G needle. Gowth 
of the tumours was monitored by visual inspection and measurement of size using 
callipers. 
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2.7.5 Analysis of murine tissues for presence of tumour 
Mice were sacrificed at the appropriate endpoint as per protocol and tissues harvested for 
FACS analysis and immunohistochemistry. After macroscopic examination of the animal 
for visible signs of tumour and measurement of the spleen weight, the long bones (2 
femurs and 2 tibias), liver and spleen were harvested. Half of each organ was preserved in 
10% formaldehyde for immunohistochemistry while half of each spleen and two bones 
were used to prepare single cell suspensions for flow cytometry. Bone marrow (BM) 
suspensions were prepared from two femurs and one tibia.  BM was flushed out with 
RPMI and 10% FCS using a 5 mL syringe attached to a 26-gauge needle and put through 
a 40µM cell strainer (BD, Oxford, UK) and collected into a 50 mL polypropylene tube.  
The spleen was cut up and eased through a 40µM cell strainer using the plunger of a 
sterile 1 mL syringe, flushed through with RPMI and 10% FCS  and collected into a 50 
mL polypropylene tube .  The cell suspensions were pelleted at 1500 rpm (400G) for 10 
minutes.  The supernatant was removed and the cell pellet was re-suspended.  Red cell 
lysis was performed with 2mL red cell lysis buffer (155mM NH4Cl, 20mM NaHCO3, 
1mM EDTA; BDH, Poole, UK) for 4 minutes on ice.  The cells were pelleted at 1500 rpm 
(400G) for 10 minutes and washed once in 10 mL of  RPMI /10% FCS.  Cell counts, 
viability and immnostaining were performed.   
 
2.7.6 Analysis of murine tissue for AAV vector biodistribution 
AAV8 transduced mice were sacrificed, organs harvested and snap frozen in liquid 
nitrogen. 50 mg of each organ was dissected and homogenised in liquid nitrogen using a 
sterile mortar and pestle. Genomic DNA was then extracted using a commercial kit 
(DNeasy Blood & Tissue kit 69506, Qiagen). After DNA quantitation samples were used 
for human FIX and murine β-actin PCR (for details see section 2.5.2). 
 
2.7.7 Statistical analysis 
Where appropriate statistical comparisions were made to look for significant differences 
between groups of data. Results are usually expressed as the mean +/- standard error of 
the mean (SEM). The paired Student t test and the Mann Whitney U test were employed 
using Graphpad Prism version 3 software (Graphpad, San Diego). For animal survival 
analysis Kaplan Meier curves were plotted and the log rank test used to analyse 
significance. A p value < 0.05 was considered to be statistically significant.
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3.1 Introduction 
The purpose of this thesis was to investigate the role of angiogenesis in haematological 
malignancies such as acute myeloid leukaemia (AML), multiple myeloma (MM) and Non 
Hodgkins lymphoma (NHL) and to evaluate the effect of inhibiting angiogenesis on 
tumour progression. The antitumour effects of inhibiting angiogenesis are best explored 
in vivo using murine models of haematological malignancies. Murine models allow one 
to mimic the human phenotype of tumours either by implanting human tumour cell lines 
into immunodeficient mice (xenografts) or by using transgenic models where key tumour 
related genes are either deleted, mutated or overexpressed. Although transgenic murine 
models for AML, MM and NHL exist they are limited by poor reproducibility, failure to 
resemble the heterogenous phenotype of human tumours seen in patients and the relative 
inability to evaluate therapeutic strategies. Several xenograft models have therefore been 
developed by injecting both tumour cell lines and primary tumour cells into different 
strains of immunocompromised mice. In this chapter we discuss the tumour models 
chosen for our experiments. Some of the models have previously been described whilst 
some were either adapted or developed in our laboratory to be more suitable for our 
research goals. 
We chose two different types of immunodeficient mice to evaluate tumour engraftment – 
the B6.CB17-Prkdcscid strain (B6-SCID) and the β2mtm1UncNOD-Prkdcscid strain (β2mnull 
NOD/SCID). Both these strains lack functional B and T cells due to defects in 
immunoglobulin and T cell receptor gene rearrangement. In addition β2mnull NOD/SCID 
mice are MHC class I deficient, complement deficient and have virtually no NK cells. At 
the outset of our work most of the previously described models had used the B6-SCID  
and NOD/SCID strains for human tumour engraftment with very limited information 
available on the β2mnull NOD/SCID strain. We therefore compared the B6-SCID and 
β2mnull NOD/SCID strains by performing engraftment experiments using AML, MM and 
NHL cell lines as well as primary cells with a view to identifying the most appropriate 
strain to use for our tumour models. 
 
3.2 Acute myeloid leukaemia xenograft models 
The HL-60 AML cell line was previously shown to engraft with varying degrees of 
success in NOD/SCID mice (Dias et al., 2001). We used this cell line and injected 1x107 
cells into the tail vein of B6-SCID and β2mnull NOD/SCID mice with or without prior 
sublethal irradiation. Mice were bled on alternate weeks to assess the presence of 
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circulating leukaemic cells and the time taken to develop hind limb paralysis, secondary 
to tumour infiltration, was assessed. As shown in Table 3.1 almost all β2mnull NOD/SCID 
mice developed leukaemia in contrast with B6-SCID mice, none of whom showed 
evidence of leukaemia even at 12 weeks. Irradiation did not appear to make any 
difference to tumour engraftment. Circulating blasts were usually identified at three 
weeks following tumour injection, by human CD45 (hCD45) FACS analysis (Figure 3.1) 
and by H&E staining of peripheral blood smears (Figure 3.2). The median time to 
develop hind limb paralysis was 37 days at which point mice were culled. Post mortem 
analysis of these mice revealed significant leukaemic infiltration in bone marrow (Figure 
3.3), spleen and liver (Figure 3.4) and to a lesser degree in lung, peritoneum and 
paraspinal tissue (Figure 3.5). Since our eventual aim was to evaluate antiangiogenic 
strategies we stained for murine vasculature using an anti-murine CD31 antibody. Clear 
evidence of increased tumour associated microvasculature could be demonstrated both 
qualitatively (Figure 3.6) and quantitatively (Figure 3.7). 
 
Table 3.1 Engraftment of haematological tumour cell lines in immunodeficient mice 
Cell line injected Mouse strain Proportion with 
tumours 
Median time to 
hind limb paralysis 
(days) 
β2mnull NOD/SCID  7/8* 37 
HL-60 
B6-SCID 0/4 n/a 
β2mnull NOD/SCID  8/8 18 
Raji 
B6-SCID 3/4 35 
β2mnull NOD/SCID  11/12 23 
U937 
B6-SCID 3/4 45 
β2mnull NOD/SCID  7/8 37 
ARH77 
B6-SCID 2/4 38 
* 1/8 mice died early from radiation related toxicity 
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Figure 3.1 Flow cytometry demonstrating leukaemic cells (hCD13+ve/hCD45+ve) in 
peripheral blood of HL-60 injected β2mnull NOD/SCID mouse (right). Control 
uninjected mouse blood (left). 50µl of whole blood was stained with anti-human 
CD13 and CD45 antibodies followed by red cell lysis, washing and then analysis on a 
flow cytometer 
 
 
Figure 3.2 Blood film from a HL-60 injected mouse showing circulating leukaemia 
blasts interspersed with normal neutrophils (Magnification x40). Circulating blast 
percentage was calculated by counting a total of 100 white blood cells at low 
magnification. 
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Figure 3.3 Human CD45 immunohistochemistry - bone marrow of HL-60 engrafted 
mouse (right) showing almost complete effacement of the marrow by hCD45 positive 
leukaemic cells. A normal control mouse bone marrow is shown on the left 
displaying normal architecture and absence of hCD45 +ve cells (Magnification x20)  
 
 
Figure 3.4 Human CD45 immunohistochemistry – section through liver from a HL-
60 engrafted mouse (right) showing islands of hCD45+ve leukaemic cells in contrast 
to control uninjected mouse liver (left) (Magnification x20)  
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Figure 3.5 Human CD45 immunohistochemistry – sagittal section of lumbar spine 
from a HL-60 engrafted mouse, taken at the onset of hind limb paralysis, showing 
vertebral body bone marrow as well as paraspinal tissue leukaemic infiltration 
(Magnification x20) 
 
 
Figure 3.6 Sections of paraspinal tissue showing increased neovasculature in a 
leukaemic mouse (right) compared to a control β2mnull NOD/SCID mouse (left) using 
murine CD31 staining (Magnification x10) 
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Figure 3.7 Microvessel density comparision between normal β2mnull NOD/SCID mice 
and HL-60 engrafted mice. Hot spots with increased endothelial cells were identified 
close to the tumour and in the case of normal mice - equivalent areas on normal tissue.  
Microvessel density (cells/mm2) was quantified by two independent individuals by 
counting the number of CD31 positive endothelial cells in 10 high power fields within the 
hot spots. Significant differences in MVD in bone marrow and lumbar spine tissue were 
observed between tumour and normal mice (* p=0.006, **p=0.001 Mann Whitney U test) 
 
Having established that β2mnull NOD/SCID mice could be used consistently to engraft 
HL-60 AML cells, we went on to evaluate the engraftment of primary AML cells in this 
particular strain. 1x107 primary AML cells from three different patients with poor risk 
AML (high white count with Flt3-ITD mutation) were injected intravenously into β2mnull 
NOD/SCID mice. Mice were monitored for signs of distress and eventually culled at 6 
weeks. No circulating blasts could be identified but immunohistochemical analysis of 
organs on post mortem showed clear evidence of AML in bone marrow in all of the 
innoculated mice (Figure 3.8) (Table 3.2). We have thus been able to demonstrate reliable 
engraftment of HL-60 AML cells as well as primary AML cells in β2mnull NOD/SCID 
mice and have also been able to show evidence of increased tumour associated 
angiogenesis. 
 
 
* ** 
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Figure 3.8 Immunohistochemistry of murine bone marrow at 6 weeks post AML 
injection demonstrating human CD45+ve primary AML infiltration from 2 different 
donors. Control BM from a saline injected β2mnull NOD/SCID mouse (shown on the 
left) stained similarly with anti-hCD45 antibody (Magnification x20)    
 
 
Table 3.2 Engraftment of primary AML cells in β2mnull NOD/SCID mice 
 
 
Patient 
characteristics 
Proportion of mice with AML 
engraftment 
Patient 1 AML M4 
Flt3-ITD +ve 
WBC 308 
3/3 
Patient 2 AML M1 
Flt3-ITD +ve 
WBC 150 
5/5 
Patient 3 AML M1 
Flt3-ITD +ve 
 
3/4* 
*  ¼  mice died early from radiation related toxicity 
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3.3 Lymphoma xenograft models 
The Raji (Burkitts lymphoma) and U937 (histiocytic lymphoma) cell lines were used in 
an attempt to develop a xenograft lymphoma model. As before, we initially injected 
intravenously 1x107 lymphoma cells into both B6-SCID and β2mnull NOD/SCID mice. 
Mice were monitored for signs of distress and development of hind limb paralysis. Our 
experiments showed that although the majority of mice from both strains eventually 
developed hind limb paralysis from disease infiltration, the time of onset was markedly 
different between the two strains. As summarised in Table 3.1 the median time to hind 
limb paralysis in the U937 model was 23 days for  β2mnull NOD/SCID mice and 45 days 
for B6-SCID mice whereas in the Raji model the median times were 18 and 35 days 
respectively. Immunohistochemistry with anti hCD45 antibody showed widespread Raji 
cell infiltration in most organs with bone marrow, spleen and liver most severely affected 
(data not shown), in comparision to the U937 model where tumours were seen 
predominantly within the abdominal cavity fixed to the peritoneum  (Figure 3.9) (Table 
3.3). We were thus able to prove that both B6-SCID and β2mnull NOD/SCID strains could 
be used to engraft lymphoma cells. 
 
 
Figure 3.9 Abdominal tumour from a U937 cell line injected β2mnull NOD/SCID 
mouse 
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Table 3.3 Biodistribution of disease in xenograft models of haematological 
neoplasms 
 HL-60 ARH77 KMSBM Raji U937 
Bone marrow +++ +++ +++ +++ + 
Blood +++ - - + - 
Spleen +++ +++ - +++ + 
Liver +++ +++ + +++ + 
Lymph nodes +++ + - +++ ++ 
Lungs ++ + - ++ - 
Kidneys + + - + - 
Peritoneum +++ ++ - +++ +++ 
+++ >75% tumour infiltration by immunohistochemistry or FACS or H@E staining, 
++ 25-75% tumour infiltration, + <25% tumour infiltration, - no evidence of tumour 
 
One of the major differences between the B6-SCID and β2mnull NOD/SCID strains is said 
to be the relative lack of NK cells in the latter and this may explain its greater 
susceptibility to tumour engraftment. We tested this hypothesis by harvesting spleen cells 
from both strains of mice and staining for NK cells. As shown in Figure 3.10 FACS 
analysis confirms the presence of greater numbers of NK cells in the B6-SCID strain. 
 
 
Figure 3.10 FACS plot illustrating the presence of CD3-ve DX5+ve  NK cells in B6 
SCID mice in contrast with the β2mnull NOD/SCID strain. Representative FACS plots 
from spleen cells of a single mouse from each strain. Atleast 5 mice from each strain were 
analysed similarly. 
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3.4 Multiple myeloma xenograft models 
The ARH77 cell line, derived from a patient with plasma cell leukaemia, was originally 
used to develop a xenograft myeloma model by systemic injection into C.B-17 SCID 
mice (Huang et al, 1993). We have adapted this model by using B6-SCID and β2mnull 
NOD/SCID mice instead. Our results show a near 100% engraftment rate with β2mnull 
NOD/SCID mice but only 50% of the B6-SCID mice appeared to engraft regardless of 
prior irradiation. Median time to onset of hind limb paralysis was similar in both groups 
(37 and 38 days respectively). Serum human immunoglobulin was detected by ELISA 
and levels were shown to increase between 2 and 4 weeks following tumour injection 
(Figure 3.11). Immunohistochemistry with anti hCD45 antibody showed widespread 
tumour infiltration in most organs (Table 3.3). We were unable to demonstrate 
hypercalcaemia or evidence of lytic bone disease by plain X-rays in our model even 
though these are pathognomonic features of myeloma in humans. 
 
Figure 3.11 Serum human immunoglobulin levels measured by ELISA in a cohort of 
eight β2mnull NOD/SCID mice at 2 and 6 weeks following ARH77 tumour injection. 
 
The limitations of the ARH77 model are firstly the significant extramedullary nature of 
disease infiltration which is in contrast to the phenotype usually seen in patients and 
secondly the fact that ARH77 cells have now been shown not to be bonafide myeloma 
cells, being EBV transformed. A new xenograft model of myeloma with predominantly 
medullary disease was needed and the KMS12BM model was therefore developed jointly 
with Neil Rabin in our laboratory (Rabin et al., 2007). The KMS12BM cell line was 
originally derived from a patient with non secretory myeloma (Ohtsuki et al., 1989). It 
was shown that intravenous injection of 1x107 KMS12BM cells into β2mnull NOD/SCID 
mice resulted in reliable engraftment of tumour cells predominantly in bone marrow. 
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Immunohistochemical analysis of organs with anti-hVS38c antibody showed evidence of 
tumour as early as three weeks following tumour injection.  Hind limb paralysis occured 
at approximately 6 weeks with complete effacement of bone marrow by tumour at this 
stage. Imaging by micro computed tomography (microCT) showed clear evidence of bone 
disease in lumbar vertebrae and tibia of diseased animals (Rabin et al., 2007). My role in 
the development of this model extended to the tail vein injections, monitoring of the 
animals for paralysis, culling of the mice at the end points and harvesting and processing 
of the organs. 
 
3.5 Discussion 
We have described the development of xenograft models for acute myeloid leukaemia 
multiple myeloma and lymphoma by implantation of a number of well characterised 
tumour cell lines into B6-SCID and β2mnull NOD/SCID immunodeficient mice. We have 
shown that the β2mnull NOD/SCID strain was superior to the B6-SCID strain for 
engraftment of most tumour cell lines and have also confirmed that a relative lack of NK 
cells in the β2mnull NOD/SCID strain was one possible explanation for this.  
In our HL-60 AML model we were able to track disease progression easily by analysing 
peripheral blood for circulating leukaemic blasts using FACS analysis, making it an ideal 
model for evaluation of therapeutic strategies. Importantly we were able to show 
engraftment of primary AML cells in the β2mnull NOD/SCID strain with disease confined 
to the bone marrow thus mimicking the phenotype observed in humans. We were able to 
develop two different types of lymphoma models (Raji and U937) – either with a rapidly 
growing tumour phenotype in β2mnull NOD/SCID mice or with a more slow growing 
tumour phenotype in B6-SCID mice. The benefit of the more rapidly growing tumour is 
the ability to assess response to therapy more quickly whilst it may be argued that 
response to antiangiogenic strategies would be better seen in the more slow growing 
tumour model. With our ARH77 myeloma model, disease progression can be monitored 
by measuring serum human immunoglobulin levels enabling us to assess potential 
therapeutic responses in a relatively non-invasive manner. The KMSBM model, with a 
much slower rate of tumour growth, is potentially more suitable for assessment of bone 
disease and the antitumour efficacy of antiangiogenic strategies. 
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4.1 Introduction 
To evaluate the effects of inhibiting angiogenesis on tumour progression we decided to 
adopt a gene transfer approach using viral vectors to over express antiangiogenic genes 
either within the tumour cell or in the microenvironment of the tumour cell. Two different 
viral vector systems were used for our experiments - lentiviral and adeno-associated viral 
(AAV) vectors. The advantages of using lentiviral vectors include their high transduction 
efficiency, their ability to stably transduce non dividing cells and their large packaging 
capacity. This makes them ideal vectors to use for transduction of haematopoietic stem 
cells as well as most tumour cells with large and potentially multiple antiangiogenic 
genes. The disadvantages include the potential safety aspects of an HIV based vector and 
the lack of a suitable lentiviral packaging cell line with the consequent need to perform 
labour intensive transient transfection to produce virus. Recombinant AAV (rAAV) 
vectors have been shown to stably integrate into both dividing and non dividing cells, 
mediate long term expression and have low immunogenicity. Their limitations include the 
low packaging capacity, a variable transduction efficiency depending on the target cell 
and the development of neutralising antibodies to the viral capsid in vivo. AAV vectors 
based on serotype 2 (AAV2) were the first to be characterised and are the most widely 
used. However a number of alternative serotypes such as AAV5 and AAV8 have now 
been developed with potential advantages over AAV2. In this chapter the production, 
purification and functional assessment of our lentiviral and rAAV vectors encoding 
antiangiogenic genes will be described. 
 
4.2 Lentiviral vectors 
4.2.1 Cloning of sFlk-1-GFP, TIMP-3-GFP and IR-GFP lentiviral constructs 
Bicistronic lentiviral vectors encoding sFLK-1 or TIMP-3 along with GFP were 
previously cloned by Dr. Nathwani’s group (Figure 4.1). In addition a control vector 
expressing GFP alone was also constructed. The 8.7kbp control pCL10.1 MSCV ires-
GFP construct was cloned by ligating the 1.6kbp fragment obtained by BstE11/Not1 
restriction digest of the retroviral MSCV-ires-GFP plasmid with the 7kbp fragment 
obtained by BstE11/Not1 digest of pCL10.1 MSCV-GFP plasmid. Similarly the 11kbp 
pCL10.1 MSCV Flk-1-ires-GFP was constructed by ligating fragments from 
BstE11/Not1 digests of MSCV-Flk-1-ires-GFP and pCL10.1 MSCV Timp-3 plasmids. 
Finally the 9.4kbp pCL10.1 MSCV Timp3-ires-GFP construct was cloned by ligating 
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fragments from BstE11/Btr1 digests of MSCV Timp-3-ires-GFP and pCL10.1 MSCV 
Flk-ires-GFP plasmids. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic diagram of MSCV-ires-GFP, MSCV-mFlk-1-ires-GFP and 
MSCV-mTimp-3-ires-GFP lentiviral vectors. LTR, long terminal repeat; gag, gene 
encoding structural proteins; pol, gene encoding viral enzymes; RRE, REV responsive 
element; MSCV, murine stem cell virus promoter, ires, internal ribosome entry site 
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4.2.2 Lentiviral vector production, purification and quantitation 
Lentiviral supernatants were made by a 4 plasmid transient transfection method using 293 
T cells (for details see chapter 2). Following transfection viral supernatant was harvested 
at 36, 48 or 72 hours, centrifuged at 1500rpm (400G) for 5 minutes to remove any cell 
debris and passed through a 0.2micron cell filter. Purified virus was concentrated by 
ultracentrifugation and its biological activity quantified by transducing HeLa cells with 
polybrene and determining the proportion of GFP positive cells by FACS analysis. The 
optimum time to harvest virus following transfection was determined to be 48hrs (Figure 
4.2). The mean biological titre of the TIMP-3-GFP and Flk-1-GFP lentiviral vector 
supernatants was approximately 1x106 transducible units (TU)/ml pre-concentration and 
0.5-1x108 TU/ml following ultracentrifugation. Higher titres were achieved with the 
control IR-GFP vector of 5x106 TU/ml pre-concentration and 1-3x108 TU/ml post 
concentration. 
 
 
 
Figure 4.2 Lentiviral vector titer quantitation by Hela cell transduction pre-
concentration (histograms show mean values, error bars represent S.E.M) 
 
4.2.3 Functional assessment of lentiviral vectors 
Having shown that the lentiviral preps were biologically active by transducing HeLa cells 
we proceeded to determine whether transduced cells were able to express the vector 
encoded protein. Analysis of supernatants from transduced cells confirmed Flk-1 and 
Timp-3 expression by Western Blot (Figures 4.3, 4.4). It was also important to ensure that 
the lentiviral vector genome did not undergo rearrangement during the transduction 
process. To prove this, Southern blots were performed on transduced HeLa cells using a 
radiolabelled probe against the GFP fragment. We were able to demonstrate the correct 
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size band corresponding to the GFP fragment in Timp-3, Flk-1 and IR transduced cells 
with no extra bands thus confirming the absence of any genomic rearrangement (Figure 
4.5).  
 
 
 
 
Figure 4.3 Western blot showing tsFlk-1 expression in the supernatant of 293T cells 
transduced with MSCV-Flk-1-ires-GFP lentiviral vector. Lane 1 recombinant murine 
Flk-1 protein, lanes 2 and 3 sFlk-1 transduced 293T cell supernatants, lanes 4 and 5 
untransduced 293 T cell supernatants. 10µg of total protein loaded per well of a 10% gel 
and run under reducing conditions. 
 
 
 
Figure 4.4 Western blot showing Timp-3 expression in the supernatant of KMSBM 
myeloma cells tranduced with MSCV-Timp-3-ires-GFP lentiviral vector. Lanes 1 and 
2 KMSBM-Timp3 cell supernatant showing glycosylated (30kDa) and unglycosylated 
(24kDa) Timp-3, lanes 3 and 4 untransduced KMSBM cell supernatant. 50µl of 
supernatant harvested from 1x106 tumour cells was loaded per well of a 15% gel and run 
under reducing conditions. 
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Figure 4.5 Southern blot analysis showing correct integration pattern of the 
lentiviral vector pCL 10.1 MSCV-ires-GFP. Genomic DNA (70µg) from lentivirally 
transduced Hela cells was subjected to Kpn1 restriction enzyme digest (lane 1) or was run 
undigested (lane 2). The predicted 1.172 kb band was seen after kpn1 digest. Controls 
included kpn1 digest of genomic DNA from previously characterised oncoretroviral 
MSCV-ires-GFP vector transduced cells (lanes 4 and 5 showing predicted 921bp 
fragment) and pCL10.1 MSCV-ires-GFP plasmid DNA standards (lanes 6-9) containing 
1011-108 vector copies. The probe was directed against a GFP containing fragment as 
shown in the schematic diagram above.  
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The transduction efficiency of these vectors on a variety of haematological cell lines was 
investigated. All tumour cell lines were efficiently transduced with >90% GFP positivity 
achieved with MOIs of 10 (Table 5.1). Some tumour cells like the ARH77 plasma cell 
leukaemia cell line needed to be multiply transduced to achieve >90% GFP positivity 
with the mean intensity of fluorescence also being lower, presumably reflecting lower 
vector copy numbers. We were also able to show long term persistence of the transgene 
through multiple passage of transduced cells.  
 
4.3 Recombinant adeno associated viral vectors  
4.3.1 Cloning of rAAV vectors encoding sFlk-1, hIFNβ and hFIX 
Recombinant AAV plasmid pAV CAGG-hFIX was originally cloned by Dr Nathwani as 
described and consists of the CMV-IE enhancer, β-actin promoter, chicken β-actin/rabbit 
β-globin composite intron (CAGG), 1.6kb human FIX cDNA and a rabbit β-globin 
polyadenylation signal flanked by the AAV inverted terminal repeats (Nathwani et al., 
2001). Recombinant pAV CAGG mFlk-1 plasmid was created by excising the mFlk-1 
cDNA from AdExFlk.6His plasmid and ligating it with the pCAGGS plasmid (Davidoff 
et al., 2002) (Figure 4.6). 
 
4.3.2 rAAV 2/2, 5/5 and 2/8 vector production, purification and quantitation 
A three plasmid transient transfection method was used to make rAAV vector (see 
chapter 2). Virus was packaged with either AAV2, AAV5 or AAV8 plasmids, purified by 
heparin affinity or ion exchange chromatography and concentrated by centrifugation. The 
purity of the prep was assessed by examination of the clarity of capsid proteins on 
Coomassie Blue stained SDS-PAGE gels. Figure 4.7 shows a representative gel of rAAV 
vector post purification, demonstrating the three distinct capsid proteins with minimal 
other contaminating bands. Viral preps were quantified by DNA slot blots and the 
average titre was determined to be 1-3×1011 vector genomes/ml (vg/ml) (Figure 4.8). 
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Figure 4.6 Schematic diagram of pAV hIFNβ, pAV mFlk-1 and control pAV hFIX 
vectors. All constructs had a cytomegalovirus immediate early enhancer (CMV-IE), a β-
actin promoter, a chicken β-actin/rabbit β-globin composite intron and a rabbit β-globin 
polyadenylation signal mediating the expression of either human interferon-β, soluble 
murine Flk-1 or human factor IX. The expression cassette was flanked by either AAV-2, 
AAV-5 or AAV-8 inverted terminal repeats (ITRs). 
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Figure 4.7 Coomassie Blue stained gel of three different rAAV vector stocks post 
purification showing capsid proteins of molecular weights 87, 72 and 62kDa. 50µl of 
purifed virus was electrophoresed on a 12% SDS-PAGE gel under denaturing conditions 
and stained with coomassie blue. 
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Figure 4.8 Quantitation of rAAV8 hFIX, IFN-β and rAAV5 mFLK-1 vectors by slot 
blot analysis. 50µl of three different purified AAV vector stocks were denatured and 
transferred onto a nylon membrane at two different dilutions followed by hybridisation 
with a radiolabelled probe against the chicken β-actin/ rabbit β-globin (CAGG) sequence. 
rAAV2/8 hFIX vector standards ranging from 1011 to 107 genomes/ml as well as positive 
(previously titred rAAV2/8 hFIX vector) and negative controls (AAV8 hFIX plasmid) 
were also transferred onto the membrane. The amount of AAV vector DNA was 
quantified by measuring the amount of radioactivity on the membrane for each sample 
and comparing it with the standard curve generated from the rAAV2/8 hFIX standards. 
 
4.3.3 Transduction efficiency of rAAV vectors in vivo 
Previous studies had suggested that AAV5 and AAV8 were superior to AAV2 for in vivo 
gene transfer (Davidoff et al., 2005a). We therefore used these serotypes to evaluate 
transgene expression in the two different mouse strains used in our animal models namely 
β2mnullNOD/SCID and B6-SCID mice. In our standard experiments each animal was 
given a vector dose of 1×1011 vgs by tail vein injection. Mice were bled at two weekly 
intervals and serum levels of the protein of interest measured by ELISA. Serum protein 
levels were detectable at four weeks following AAV5 injection and as early as two weeks 
following AAV8 challenge, eventually reaching a plateau at 8 weeks (data not shown). 
Peak levels were higher with AAV8 than AAV5. Furthermore serum Flk-1 levels were 
consistently higher in B6-SCID mice than in the β2mnullNOD/SCID strain (Figure 4.9). 
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Figure 4.9 Comparision of serum Flk-1 levels between two different strains of 
immunodeficient mice following tail vein injection of 2.5 x 1011 AAV8 vector copies – 
results from β2mnullNOD/SCID mice (n=5), B6 SCID mice (n=6) and control AAV-FIX 
injected B6SCID mice (n=3) shown 
 
The biodistribution of AAV was also evaluated following in vivo transduction by PCR of 
murine tissue. As shown in Figure 4.10 the liver appears to be the predominant site of 
transgene expression although vector particles can be detected to some extent in most 
other organs by QPCR (data not shown). 
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Figure 4.10 Factor IX transgene expression within liver of mice transduced 
systemically with 2.5x1011 vector copies of rAAV8-hFIX (transduced mice + , control 
mice ⎯). 1µg of genomic DNA extracted from murine organs (12 weeks post 
transduction) was subjected to PCR using primers that amplified a 681bp region of hFIX 
cDNA. Standards consisting of serial dilutions of AAV-hFIX vector DNA in negative 
genomic DNA were used to quantitate proviral copy number. Simultaneous PCR of the 
housekeeping murine β-actin gene (604 bp region + larger splice variant) was performed 
to ensure equivalent DNA amounts for each sample. 10µl of the 50µl PCR reaction was 
run on a 1.5% agarose gel as shown above. 
 
4.4 Discussion 
We have optimised the conditions for production of purified high titre lentiviral vectors. 
The ability of our lentiviral constructs to transduce a wide variety of haematological cell 
lines with high efficiency was demonstrated. Long term transgene expression as a result 
of lentiviral vector integration into the host cell genome was clearly shown.  
With respect to rAAV vectors, we have again been able to develop a methodology to 
produce reasonably pure, high titre AAV5 and AAV8 vectors. The transduction 
efficiency of AAV5 and AAV8 vectors on haematopoietic cell lines in vitro is not much 
higher that with AAV2 vector but in vivo we have shown high and long term transgene 
expression following systemic administration of both these vectors, with AAV8 serotype 
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giving the best results. The liver specificity of the AAV constructs was confirmed by the 
relatively high level of transcripts seen in murine liver tissue compared with other organs. 
At the outset of my work the lentiviral and AAV vector constructs had already been 
cloned but the functional evaluation of these constructs was done entirely by myself. 
Similarly optimisation of the lentiviral vector production protocol was performed by 
myself. The AAV vector purification protocol was developed in conjunction with my 
colleague Jenny McIntosh.  
Having optimised the conditions for production of our lentiviral and rAAV vectors and 
assessed their transduction efficiency in vitro and in vivo, we were then able to proceed 
towards evaluating the effect of viral vector mediated antiangiogenic gene transfer on 
haematological tumour progression in xenograft models. 
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5.1 Introduction 
Matrix metalloproteinases (MMPs) play an important role in promoting angiogenesis and 
tumour growth. They are mainly produced by stromal cells as well as many tumour cells 
and are responsible for proteolytic degradation of the extracellular matrix, a prerequisite 
for angiogenesis as well as tumour metastases. They also have direct effects on tumour 
and endothelial cells with both pro and antiapoptotic properties. A positive correlation has 
been shown between MMP expression and the invasive and metastatic potential of many 
solid tumours including colon, lung, breast, ovarian and prostate carcinoma. A number of 
synthetic MMP inhibitors have been developed which have shown impressive antitumour 
effects in preclinical solid tumour models. Their results in clinical trials however have 
been largely disappointing. 
MMP activity is regulated by the Tissue inhibitors of metalloproteinases (TIMPs 1-4). 
There has been increasing interest in the use of these endogenous MMP inhibitors, in 
particular TIMP-3, for their antiangiogenic and potentially antitumour effects. TIMP-3 is 
distinct from the other TIMPs in having a high binding affinity for the extracellular 
matrix as well as having a greater specificity for the adamalysin metalloproteinases 
(ADAMs) in addition to inhibiting most MMPs (Leco et al., 1994; Murphy et al., 2003). 
It is proapoptotic and uniquely has the capacity to block angiogenesis directly by 
preventing VEGF binding to its signaling receptor VEGFR-2 (Qi et al., 2003). In vitro 
studies have shown that over expression of TIMP-3 in melanoma, cervical carcinoma and 
sarcoma cell lines inhibited their ability to invade through Matrigel (Ahonen et al., 1998; 
Baker et al., 1999). Furthermore TIMP-3 over expression was shown to inhibit tumour 
formation in murine xenograft models of melanoma, squamous cell carcinoma and breast 
carcinoma (Ahonen et al., 2002; Anand-Apte et al., 1996). However the therapeutic 
effects of TIMP-3 in haematological malignancies had not been evaluated previously. We 
therefore investigated the effects of TIMP-3 over expression in xenograft models of 
myeloma and acute myeloid leukaemia and the results of these experiments are described 
in this chapter. 
 
5.2 Results 
5.2.1 Exogenous TIMP-3 does not affect proliferation of KMSBM, ARH-77 and 
HL-60 cell lines in vitro 
Recombinant murine TIMP-3 (rmTIMP-3) at varying concentrations (0-1 mg/ml) was 
added to myeloma and acute myeloid leukaemia cell lines in vitro, in the exponential 
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phase of growth. No obvious change in cell proliferation was observed at 24, 48 and 72 
hours by MTS assay even at the highest concentration of TIMP-3 (Figures 5.1A, 5.2A). 
 
    A      B 
 
 
Figure 5.1 MTS assays showing the effects of exogenous (A) and endogenous (B) 
Timp-3 on the proliferation of KMSBM cells at 72 hours. O.D. measurements were 
done in triplicates (mean and S.E.M values shown on graph) with the assay repeated 
twice. No correlation was seen between recombinant Timp-3 concentration and KMSBM 
proliferation (Pearson rank correlation p=0.577) and no statistically significant difference 
was seen with endogenous Timp-3 expression (Mann Whitney U test p=0.072)  
 
    A      B 
 
 
Figure 5.2 MTS assays showing the effect of exogenous (A) and endogenous (B) 
Timp-3 on the proliferation of HL-60 cells at 72 hours. O.D. measurements were done 
in triplicates (mean and S.E.M values shown on graph) with the assay repeated twice. No 
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correlation was seen between recombinant Timp-3 concentration and HL-60 proliferation 
(Pearson rank correlation p=0.876) and no statistically significant difference was seen 
with endogenous Timp-3 expression (Mann Whitney U test p=0.070)  
 
    C 
 
Figure 5.2 C. MTS assay showing the effect of different levels of Timp-3 endogenous 
expression on the proliferation of HL-60 cells at 72 hours. Mean of triplicate O.D 
measurements shown with S.E.M error bars. No significant difference between groups by 
one way ANOVA test (p=0.195) 
 
5.2.2 Endogenous TIMP-3 expression does not affect proliferation of KMSBM, 
ARH-77 and HL-60 cell lines in vitro 
We next sought to determine whether TIMP-3 could have a direct effect on tumour cell 
proliferation when expressed endogenously. Tumour cells were transduced with 
bicistronic lentiviral vectors encoding either murine TIMP-3 and GFP or GFP alone. 
Transduction was performed on consecutive days in serum free conditions in the presence 
of polybrene, using an MOI of 10 (see Methods). Variable levels of transduction were 
seen depending on the type of tumour cell. Transduction efficiency was highest with 
KMSBM cells and lowest with ARH-77 (Table 5.1). All transduced cell lines were sorted 
for GFP by flow cytometry to give a 100% GFP+ve population. Furthermore transduced 
HL-60 cells were also sorted into low and high GFP expressing cells. No difference in 
cell proliferation was seen between TIMP-3 and control GFP transduced cells by MTS 
assay at 48 or 72 hours (Figures 5.1B, 5.2B). Furthermore there was no difference in 
proliferation between the low and high TIMP-3-GFP expressing HL-60 cells (Figure 
5.2C). 
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Table 5.1 Transduction efficiency of Flk-GFP, Timp-3-GFP and control IR-GFP 
lentiviral vectors on myeloma and leukaemia cell lines. 
Vector HL-60 (%GFP) KMSBM (%GFP) ARH77 (%GFP) 
IR-GFP 90.9 98 11.3 
Flk-GFP 63.1 96 9.1 
Timp-3-GFP 82 72 8.7 
 
 
5.2.3 Effect of TIMP-3 expression in xenograft murine models of myeloma and 
leukaemia 
 
5.2.3.1 Effect of TIMP-3 expression in the KMSBM myeloma model 
The effect of TIMP-3 expression in vivo against myeloma cells was then investigated 
using the KMSBM myeloma model. In this model tumour infiltration within the bone 
marrow of β2mnullNOD/SCID mice occurs within six weeks of tumour injection leading 
to hind limb paralysis (see Chapter 3 for details). Cohorts of  β2mnullNOD/SCID mice 
were injected intravenously with 1×107 TIMP-3-GFP (n=5) or control GFP (n=5) 
transduced KMSBM cells. In both cohorts tumour cells were 100% GFP positive prior to 
injection. Six weeks after tumour injection, levels of tumour infiltration in both cohorts 
were assessed by FACS analysis of bone marrow single cell suspensions and confirmed 
by immunohistochemistry.  
FACS analysis showed a significant difference in tumour infiltration between the two 
cohorts as measured by the proportion of GFP expressing cells in bone marrow (p=0.015 
Mann Whitney U test). The mean proportion of tumour cells in the TIMP-3-GFP cohort 
was 4.68% (±1.04) compared with 48.43% (±10.53) in the control GFP cohort (Figure 
5.3). 
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Figure 5.3 FACS analysis demonstrating significantly reduced tumour burden in 
bone marrow of mice injected with Timp-3 transduced KMSBM cells compared 
with control IR-GFP KMSBM injected mice. Top histogram shows mean tumour 
infiltration (error bars show S.E.M) within bone marrow in a cohort of 4 KMSBM-ires-
GFP mice compared with that in a cohort of 5 KMSBM-Timp-3-GFP mice. 
Representative FACS plots shown in lower panel. 
 
Immunohistochemistry using anti-GFP and anti-VS38c antibodies also confirmed the 
inhibitory effect of TIMP-3 expression on KMSBM tumour infiltration in vivo. Within 
the IR-GFP cohort 4 out of 5 mice showed high levels of bone marrow tumour infiltration 
(1 early death occurred from infection) compared with the Timp-3-GFP cohort where 3 
out of 5 had no evidence of disease and the remaining two had only minimal disease 
(Figure 5.4). 
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Figure 5.4 Immunohistochemistry and FACS analysis showing tumour infiltration 
of murine bone marrow from two cohorts of mice infused with either KMSBM-ires-
GFP or KMSBM-Timp-3-GFP Bone marrow from mice injected with IR-GFP (NOD1-
4) or Timp-3-GFP transduced KMSBM cells (NOD5-9) was harvested at 6 weeks post 
tumour injection and paraffin embedded sections stained with either anti-VS38c or anti-
GFP antibodies. Single cell bone marrow suspensions were also analysed for GFP 
positivity by FACS analysis as shown above.  
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5.2.3.2 Effect of TIMP-3 expression in the ARH77 myeloma model 
To determine whether the inhibitory effect of TIMP-3 expression in vivo would be seen 
with other myeloma cell lines, the above experiment was repeated with transduced 
ARH77 cells. As before tumour cells used for these in vivo experiments were 100% GFP 
positive. TIMP-3-GFP or control GFP transduced ARH77 cells were then injected into 
β2mnull NOD/SCID mice (n=4 for each cohort). Tumour infiltration in bone marrow was 
assessed at four weeks following tumour inoculation. Tumour load was found to be low 
in all mice but there was no significant difference seen between the TIMP-3-GFP and 
control GFP cohorts (Figure 5.5). 
 
 
Figure 5.5 FACS analysis showing no significant difference in tumour burden 
between ARH77-Timp-3 and control IR-GFP tumour injected mice Histograms show 
mean GFP percent values from a single experiment involving 4 mice in each group, error 
bars represent S.E.M. Mann Whitney U test shows no significant difference between IR 
transduced or Timp-3 transduced ARH-77 groups (p= 0.342) 
 
 
5.2.3.3 Effect of TIMP-3 expression in  the HL-60 leukaemia model 
The effect of TIMP-3 expression on HL-60 cell proliferation in vivo was also evaluated in 
a similar way. TIMP-3-GFP or control GFP transduced HL-60 cells were injected 
intravenously into cohorts of β2mnull NOD/SCID mice (n=6 for each cohort). Four weeks 
later mice were culled and tumour load assessed in each of the mice by GFP FACS 
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analysis and immunohistochemistry. Variable levels of tumour infiltration were seen in 
bone marrow and spleen but with no significant difference between the TIMP-3-GFP and 
control GFP cohort (Figure 5.6). 
 
 
  
Figure 5.6 Comparision of tumour infiltration by GFP FACS analysis between 
cohorts of mice given control transduced or Timp-3 transduced HL-60 leukaemic 
cells. Histograms show mean values from a single experiment involving 5 mice in each 
group, error bars represent S.E.M. Mann Whitney U test shows no significant difference 
between IR transduced or Timp-3 transduced HL-60 groups (p= 0.428) 
 
5.3 Discussion 
Our work has clearly demonstrated that TIMP-3 does have a profound antitumour effect 
on KMSBM myeloma cells in vivo when expressed endogenously. The mechanisms 
underlying the antitumour effect of TIMP-3 in this model include inhibition of 
extracellular matrix degradation thereby preventing angiogenesis and tumour invasion, 
and direct blockade of VEGF binding to its receptor thereby directly inhibiting 
endothelial as well as tumour cell proliferation. The possibility that TIMP-3 expression 
may have negatively influenced homing of KMSBM tumour cells to the bone marrow 
cannot be entirely ruled out. No significant antitumour effects were seen with the ARH77 
myeloma cell line or the HL60 AML cell line in vivo. There are several possible reasons 
for this difference. Firstly it might be that TIMP-3 has a greater apoptotic effect against 
KMSBM cells than ARH77 or HL-60 cells in vivo despite not having any discernible 
direct effect on any of these tumour cell lines in vitro. Secondly it is possible that 
angiogenesis has a more important  role in KMSBM tumour progression than with 
ARH77 or HL60. Thirdly the level of TIMP-3 expression may be crucial in determining 
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the extent of its antiangiogenic and antitumour effects. FACS analysis shows 100% GFP 
positivity in all three of the transduced cell lines but mean fluorescence was significantly 
higher in KMSBM cells compared with ARH77 or HL-60 indicating that TIMP-3 
expression in KMSBM cells was also likely to be correspondingly higher. Furthermore 
the expression levels of tumour secreted MMPs may differ between the tumour cell types 
requiring higher levels of TIMP-3 in some tumours to produce the same degree of 
antiangiogenesis and tumour inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
 
 
 
 
 
 
CHAPTER	  6	  :	  EFFECTS	  OF	  VEGF	  PATHWAY	  
BLOCKADE	  IN	  MODELS	  OF	  ACUTE	  MYELOID	  
LEUKAEMIA	  AND	  NON-­HODGKIN’S	  LYMPHOMA
99 
 
6.1 Introduction 
VEGF is one of the principal proangiogenic factors involved in regulating tumour 
associated neovasculature, not only in solid tumours but also in haematological 
malignancies like AML and myeloma. Current evidence supports the hypothesis that 
haematological tumour cells, endothelial cells (ECs) and bone marrow stromal cells 
(BMSCs) closely interact with each other in the bone marrow to facilitate tumour 
progression, mediated to a large extent by VEGF. VEGF expression has been 
demonstrated on most AML, myeloma and lymphoma cell lines and primary cells as well 
as BMSCs (Bellamy et al., 1999; Fiedler et al., 1997). VEGF has been shown to promote 
endothelial cell proliferation and migration (Rousseau et al., 2000). Studies have also 
demonstrated that VEGF inhibits apoptosis and stimulates proliferation and migration of 
leukaemic and myeloma cells through autocrine and paracrine pathways (Dias et al., 
2000; Podar et al., 2001). The biological effects of VEGF are mediated predominantly 
through the VEGFR-1 and VEGFR-2 receptors which are found on all adult vascular 
endothelial cells as well as most leukaemic and myeloma cells. Results from VEGFR 
knockout mouse models (Fong et al., 1995; Shalaby et al., 1995) and experiments 
involving blockade of VEGF receptors with antibodies (Dias et al., 2000) have strongly 
suggested that VEGFR-2 (also termed KDR or Flk-1) is the main receptor involved in 
endothelial and tumour cell proliferation/migration whilst VEGFR-1 (Flt-1) is more 
responsible for vascular remodelling.  
We have investigated the effects of blocking VEGFR-2 in xenograft models of AML and 
lymphoma by viral vector mediated gene transfer of the truncated, soluble, ligand-binding 
extracellular domain of the murine Flk-1 receptor. The soluble Flk-1 receptor can 
potentially inhibit the VEGF pathway firstly by binding either tumour secreted human 
VEGF or host stromal tissue secreted murine VEGF and secondly through a dominant 
negative mechanism by forming non functional heterodimers with endogenous VEGF 
receptors present on both tumour cells and host endothelial cells. We have also evaluated 
the effects of blocking the VEGF pathway using a humanised anti-VEGF antibody 
(Bevacizumab, Genetech) in these models. This antibody binds predominantly tumour 
secreted human VEGF with minimal binding to murine VEGF (Yu et al., 2008). 
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6.2  Results of VEGF pathway blockade in AML and lymphoma models 
 
6.2.1 Expression of sFLK-1 and hFIX in vivo following AAV viral vector mediated 
gene transfer in β2mnull NOD/SCID mice 
In this experiment 2.5×1011 vgs of either AAV5/5 sFlk-1 or AAV5/5 hFIX viral vector 
per animal were injected into the tail veins of two cohorts of β2mnull NOD/SCID mice. 
Subsequent expression of sFlk-1 and hFIX in vivo was evaluated by ELISA at timepoints 
of 4 and 12 weeks. In the sFlk-1 transduced cohort (n=5) plasma sFlk-1 levels of 490-
3700 (median 720) ng/ml were detected at 4 weeks, rising to 2500-5800 (median 3400) 
ng/ml at 12 weeks (Figure 6.1). Similarly plasma hFIX levels of 200-350 (median 300) 
ng/ml were detected in the control hFIX transduced cohort (n=5). 
 
 
 
Figure 6.1 Plasma Flk-1 levels in β2mnull NOD/SCID mice transduced with AAV5/5 
Flk-1 vector . 
 
6.2.2 Effect of sFLK-1 expression in a leukaemia xenograft model  
Having established stable systemic transgene expression, 1×107 HL-60 leukaemic cells 
were injected intravenously into both sFlk-1 and control hFIX transduced mice. At 4 
weeks following tumour injection, with several animals now showing signs of being 
unwell, all mice were culled and tumour load evaluated. There was no significant 
difference in average spleen weight between the sFlk-1 and control hFIX transduced 
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cohorts. FACS analysis using anti-human CD45 antibody showed no significant 
difference in tumour load within bone marrow or spleen between the two cohorts (Figure 
6.2). Immunohistochemistry with anti-human CD45 antibody also confirmed that there 
was a similar degree of leukaemic infiltration in both cohorts of mice (data not shown). 
 
    A      B    C 
 
Figure 6.2 FACS data showing no difference in HL-60 tumour infiltration of bone 
marrow (A) or spleen (B) between FIX and sFLK-1 transduced mice (p=0.142 and 
p=0.571 respectively, Mann Whitney U test). Plot C shows comparision of spleen 
weights between the two cohorts (p=0.45 Mann Whitney U test). 
 
6.2.3 Effect of sFLK-1 expression in a lymphoma xenograft model  
For this experiment 1×1011 vgs of AAV5/5 sFlk-1 or AAV5/5 hFIX vector were injected 
into cohorts of B6 SCID mice. At 4 weeks following gene transfer, plasma samples were 
screened for sFlk-1 expression by ELISA and levels of 128-3679 (median 4800) ng/ml 
were detected in the sFlk-1 transduced cohort (n=7) which increased to 1605-8730 
(median 4786) ng/ml by 14 weeks (Figure 6.3A). hFIX expression was confirmed in the 
control cohort (n=5).  
Having established stable transgene expression, 1×107 Raji lymphoma tumour cells were 
injected intravenously into each animal from both cohorts. Mice were closely monitored 
and culled at the earliest signs of disease related distress or hind limb paralysis. The 
presence and extent of tumour infiltration were evaluated by hCD45 
immunohistochemistry. Expression of sFlk-1 failed to protect the mice from developing 
tumour infiltration as demonstrated by the survival curves in Figure 6.3B. There was a 
trend for sFlk-1 expressing mice to die earlier than controls but the difference was not 
statistically significant (p value =0.5). 
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Figure 6.3 A. Serum sFlk-1 levels by ELISA in B6 SCID mice which were injected 
with 1x107 Raji tumour cells 6 weeks after transduction with AAV5-sFlk-1 (left) B. 
Kaplan-Meir plots showing no improvement in survival in these mice compared to 
Raji injected hFIX expressing mice (right) p=0.505 Log-rank test. 
 
6.2.4 Effect of VEGF pathway blockade using a recombinant humanised anti-
VEGF antibody in a leukamia xenograft model 
An alternative method of blocking the VEGF pathway is to use a monoclonal antibody 
directed against VEGF (Bevacizumab). We evaluated the effect of using a recombinant 
humanised anti-VEGF antibody in our leukaemia xenograft model. Three cohorts of 
β2mnull NOD/SCID mice were injected intravenously with 1×107 HL-60 cells per animal. 
A week later two of the cohorts were injected with 5×1010 viral genomes of either 
AAV5/5 sFlk-1 (n=6) or AAV5/5 hFIX (n=6) per animal intravenously. Animals from the 
third cohort (n=6) were each injected with 5mg/kg of anti-VEGF antibody 
intraperitoneally three times a week. Expression of sFlk-1 in the AAV sFlk-1 transduced 
cohort was confirmed by ELISA with a mean plasma sFlk-1 level of 3890 (range 1632-
4988) ng/ml. Similarly hFIX expression was confirmed in the control cohort. Stable 
levels of anti-VEGF antibody in plasma was also demonstrated by ELISA in the antibody 
treated mice. 
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    A           B 
 
Figure 6.4 Serum` sFlk-1 levels and VEGF Antibody levels measured in AAV-Flk 
transduced mice (A) and VEGF Antibody treated mice (B) respectively. ELISA done 
either 4 weeks post AAV injection or 24 hours post antibody injection following 4 
weeks of treatment  
 
The effect of sFlk-1 expression and anti-VEGF antibody treatment on serum VEGF levels 
in vivo was determined. Serum human VEGF levels were measured by ELISA and mean 
levels from the above three cohorts compared. No significant difference in mean human 
VEGF levels was seen although levels were generally low throughout (Figure 6.5). 
Furthermore no difference in serum murine VEGF levels was seen in any of the animals 
(data not shown). 
 
 
Figure 6.5 Serum human VEGF ELISA showing similarly low levels of human 
VEGF in HL-60 injected mice regardless of whether they were transduced with 
AAV-sFlk-1 or AAV-FIX or treated with VEGF antibody (5mg/kg). A cohort of non 
tumour untransduced control mice was also included. 
 
Analysis of tumour load at the end of four weeks showed no significant difference in the 
degree of tumour infiltration between the control hFIX and the sFlk-1 transduced cohorts. 
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However the VEGF antibody treated mice, surprisingly, appeared to have significantly 
increased tumour infiltration (Figure 6.6). 
 
Figure 6.6 FACS analysis results showing tumour burden in bone marrow and 
spleen of HL-60 injected mice treated with AAV-FIX, AAV-sFlk-1 or VEGF 
antibody (5mg/kg) Histogram shows mean values from groups of 6 mice with error bars 
representing S.E.M. *p=0.121 **p=0.0001, °p=0.489 °°p=0.0001 (t test) 
 
In a further experiment the effect of VEGF antibody dose titration on HL-60 cell 
proliferation in vivo was evaluated. Four cohorts of β2mnull NOD/SCID mice were 
injected intravenously with 1×107 HL-60 cells per animal. Three of the cohorts were 
subsequently treated with anti-VEGF antibody at doses of 0.5, 1 or 5 mg/kg, administered 
three times a week intraperitoneally (n=4 each cohort). Animals from the control cohort 
on this occasion were each injected with 12.5 µg/ml of anti RhD antibody using the same 
regime. Comparision of tumour load at four weeks showed no difference between mice 
treated with the 5 mg/kg dose of VEGF antibody and the anti RhD treated control mice. 
However the cohorts treated with the lower doses of antibody did show slightly higher 
tumour infiltration than the control cohort although this was not statistically significant 
(Figure 6.7). 
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Figure 6.7 FACS analysis results showing effects of VEGF antibody dose on bone 
marrow tumour burden in HL-60 injected mice Mean values with S.E.M shown from 
a single experiment with 4 mice per group. No statistically significant correlation was 
seen p=0.599 (Pearson rank correlation). Control mice (labelled as 0 mg/kg on histogram) 
were given 5mg/kg of anti-RhD antibody 
 
6.2.4 Effect of anti-VEGF antibody treatment in a lymphoma xenograft model 
Two cohorts of irradiated B6 SCID mice were injected with 1×107 Raji cells 
intravenously (n=8 each cohort). A week later one cohort was commenced on VEGF 
antibody treatment at 5mg/kg intraperitoneally three times a week. The control cohort 
was treated with anti RhD antibody in a similar way. The time taken for mice to become 
unwell and develop hind limb paralysis as a result of tumour proliferation was noted. The 
survival curves in Figure 6.8 show that treatment with VEGF antibody failed to prevent 
tumour infiltration in this lymphoma model. 
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Figure 6.8 Kaplan-Meir plot showing no difference in survival of Raji injected mice 
between anti-VEGF antibody and saline treated cohorts (p=0.1289 log Rank test, n=8 
each cohort) 
 
6.3 Discussion 
The results of our work show that blocking the VEGF pathway, either by expressing the 
soluble Flk-1 receptor or by administering an anti-VEGF antibody, does not result in any 
significant antitumour effects in our leukaemia or lymphoma xenograft models. One 
possible explanation for the lack of therapeutic benefit  might be that the level of VEGF 
pathway blockade achieved was suboptimal. However the serum levels of sFLK-1 and 
anti-VEGF antibody achieved in our in vivo experiments far exceeded the doses 
previously shown to inhibit angiogenesis in vitro (Davidoff et al., 2002). An alternative 
explanation is that excessive blockade of the VEGF pathway leads to the development of 
tumour resistance by a compensatory increase in VEGF levels either from the tumour cell 
or from host tissue. Such a phenomenon was demonstrated by Davidoff (Davidoff et al., 
2005b) in a neuroblastoma murine model where significant antitumour efficacy was seen 
in mice with low levels of Flk-1 expression in contrast to mice with high Flk-1 levels 
where tumour progression was much more aggressive. Furthermore tumour resistance in 
these mice was shown to be mediated by increased VEGF expression from tumour cells 
and murine tissue. We were unable to demonstrate increased serum levels of murine or 
human VEGF with Flk-1 expression or anti-VEGF antibody treatment. However serum 
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VEGF levels can often be quite unreliable and a better measure might be tissue VEGF 
levels. Further evidence comes from a phase II trial of colorectal carcinoma where the 
anti-VEGF antibody Bevacizumab was found paradoxically to be less effective at the 
higher of the two doses used suggesting that optimal inhibition of angiogenesis may 
depend crucially on the dose of antiangiogenic agent used. Our experiments using 0.5, 1 
and 5 mg/kg doses of anti-VEGF antibody were not able to demonstrate therapeutic 
efficacy against AML cell proliferation in vivo. In fact there appeared to be a greater 
tumour burden in mice treated with the anti-VEGF antibody compared to controls. Finally 
it may be that antiangiogenic strategies like VEGF signalling blockade on its own may 
simply be inadequate to arrest the growth of rapidly proliferating tumour types like AML. 
A more effective strategy for antiangiogenesis might be to use it in combination with 
more conventional cytotoxic therapies, in the setting of minimal residual disease.  
In summary our work has shown that stably blocking the VEGF pathway either by 
expressing the soluble Flk-1 receptor or by using an anti-VEGF anyibody does not inhibit 
tumour progression in our HL-60 AML and Raji lymphoma models. Further work needs 
to be done looking at different levels of VEGF blockade and by using combination 
chemotherapeutic agents before abandoning them as potential therapeutic strategies in 
AML and lymphoma. 
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7.1  Introduction 
Interferons (IFNs) are a family of cytokines that have significant antitumour activity. The 
antitumour properties of the type I IFNs (α/β) are a consequence of their antiproliferative, 
immunomodulatory and antiangiogenic effects. Despite the impressive antitumour 
efficacy of IFN-α in xenograft models of solid tumours, the results from clinical trials 
have been far more disappointing. The main limiting factors in the clinical use of 
recombinant type I IFNs are their short half-life and the side effects associated with peak 
levels. IFN-α has been used with variable success in a number of paediatric vascular 
neoplasms, metastatic melanoma and renal cell carcinoma. In the field of haematological 
malignancies IFN-α has been shown to be efficacious in hairy cell leukaemia, chronic 
myeloid leukaemia and multiple myeloma but no obvious therapeutic benefit was seen in 
AML.  
There has been increasing interest recently in the use of IFN-β for the treatment of 
malignancies with many reports suggesting that IFN-β has more potent antitumour effects 
than IFN-α. However IFN-β has not previously been evaluated in the treatment of AML. 
In this chapter we report a detailed evaluation of the antileukaemic effects of human IFN-
β in vitro and in a xenograft model of AML by using adeno-associated viral vectors to 
deliver sustained expression of IFN-β in vivo. 
 
7.2 Interferons-α/β inhibit the proliferation and survival of AML cells in vitro 
We compared the activity of recombinant human IFNα-2b and IFNβ-1a against a range of 
AML cell lines (HL-60, OCI AML5, AML193, KG1α ) in vitro using thymidine uptake 
assays. After 3 days of culture we observed significant but equivalent antiproliferative 
activity with both hIFN-α and hIFN-β against all AML cell lines. The minimum dose 
required for both agents was 10 IU/ml with a reduction in proliferation of 50-80% 
occurring at a dose of approximately 1000 IU/ml. Higher IFN concentrations did not 
result in any further reduction in AML cell proliferation (Figure 7.1).  
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Figure 7.1 Thymidine uptake assays showing the effects of IFNs– α (▲) and β (■) on 
the proliferation of AML cell lines in vitro. Cells were exposed to recombinant IFNs 
for 3 days prior to the assay. 
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We also looked at AML cell survival in response to IFN stimulation using AnnexinV 
assays and showed upto 50% increase in apoptosis at a dose of 1000 IU/ml after three 
days of culture (Figure 7.2). 
 
 
Figure 7.2 Annexin V / Propidium iodide staining of HL-60 cells exposed to 
1000IU/ml IFN-β for 72 hours at different cell densities. Cytarabine exposed HL-60 
cells were used as positive controls. 
 
7.3 Interferons-α/β affect the cell cycle of AML cells by increasing the fraction in 
S phase  
The effects of type I interferons on the cell cycle were evaluated as described in chapter 
2. These experiments showed that IFNs reduced the proportion of AML cells in G1 phase 
and increased the proportion in S phase (Figure 7.3).   
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Figure 7.3 Cell cycle analysis of HL-60 cells exposed to 1000 IU/ml of IFNs-α/β for 
72 hours Top panel shows mean values with S.E.M of HL-60 cells exposed to different 
conditions in triplicates and the experiment was done three times. Bottom two panels 
show the FACS plots of control untreated (middle panel) and IFN-β treated (lower panel) 
HL-60 cells  
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7.4 Interferons-α/β induce phosphorylation of the JAK/STAT signalling pathway 
in AML cells 
Previous work has shown that in most cells the biological effects of interferons-α/β are 
mediated through activation of the Janus activated kinase (JAK)/signal transducer and 
activator of transcription (STAT) pathway following binding of the type I IFN receptor. 
We have investigated the cell signalling pathways of AML cells in response to IFN 
stimulation and confirmed the involvement of the JAK/STAT pathway (Figure 7.4). 
 
 
Figure 7.4 Western Blot analysis of HL-60 cells exposed to IFN-β at different time 
points showing rapid phosphorylation of JAK-1 and STAT-1. Lysates from 2x106 
cells exposed to 1000IU/ml IFN-β for 10, 30 or 60 minutes were run on a 10% gel under 
reducing conditions. 
 
7.5 Effects of interferons-α/β on tumour secretion of angiogenic cytokines 
Type I IFNs have been shown to downregulate the production of proangiogenic cytokines 
by many tumour types. We decided to see if IFNs had a similar effect on AML cells. 
Following IFN stimulation, HL-60 cells were assessed by PCR for VEGF, MMP-2 and 
MMP-9 expression. No obvious difference in expression was seen between IFN 
stimulated and control HL-60 cells (Figure 7.5). 
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Figure 7.5 VEGF and MMP-2 RT-PCR of HL-60 cells treated with 1000IU/ml of 
IFN-β for 3 days. 1µg of IFN-β treated HL-60 cell RNA was subjected to PCR in 
duplicates and 20% of each PCR reaction (10µl) was run on a 1% agarose gel. For the 
VEGF PCR human endothelial cells were used as a positive control showing the 656 and 
584bp isoforms. PCR of the housekeeping gene GAPDH was done simultaneously.  
 
7.6 Recombinant hIFN-β fails to inhibit HL-60 proliferation in a xenograft model 
of AML but stable expression of interferons-α/β by AAV mediated gene transfer 
results in significant antileukaemic effects  
Having demonstrated the antileukaemic activity of hIFN-α and hIFN-β in vitro, we next 
assessed their in vivo efficacy in a xenograft model of AML. We chose to focus on hIFN-
β because of its reported stronger antiproliferative activity against other tumour types. In 
our initial experiments recombinant hIFN-β was administered either subcutaneously 
(2000 IU/mouse thrice weekly) or intravenously (60,000 IU/mouse daily) into cohorts of 
β2mnull NOD/SCID mice, a week after intravenous injection with HL-60 cells with an 
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additional untreated cohort (n=10) serving as controls. The dose administered weekly was 
approximately 3-fold or 200-fold higher respectively than the equivalent standard adult 
human dose of hIFN-β given clinically. Despite administering such high doses, hIFN-β 
was undetectable in the plasma of animals treated subcutaneously (n=4) at any time point. 
In contrast, at 2 hours after intravenous injection (n=9) the mean plasma level of hIFN-β 
was 400 IU/ml (range 200-1000) which declined to undetectable levels by 24hrs, 
consistent with its short half life. Four weeks after injection of HL-60 cells, heavy but 
equivalent levels of tumour infiltration were observed in all three cohorts (Table 7.1). 
These results contrast with the in vitro effects of hIFN-β on AML cells and may be 
explained either by its rapid clearance or by its poor biological activity in vivo.  
 
Table 7.1. Outcome of recombinant hIFN-β treatment of HL-60 leukemic mice  
Treatment cohort Proportion of 
animals with 
significant disease 
(>30% infiltration) 
‘Peak’ plasma 
hIFN-β levels 
(IU/ml) 
‘Trough’ plasma 
hIFN-β levels 
(IU/ml) 
Controls 10/10 <0.5 <0.5 
s.c. hIFN-β 4/4 <0.5 <0.5 
i.v. hIFN-β 8/10* 400 ± 100 <0.5 
* 2 early deaths from radiation toxicity 
Peak levels measured at 2 hours post injection, trough at 24 hours. 
 
To resolve this issue we established stable long-term expression of hIFN-β in vivo 
following gene transfer with AAV2/8 vectors encoding hIFN-β and subsequently 
evaluated the effects on AML cell proliferation. β2mnull NOD/SCID mice were injected 
with HL-60 cells as previously, and a week later AAV2/8 hIFN-β was administered at a 
dose of 1x1011 vector particles. Peak plasma hIFN-β levels measuring 20,000 to 100,000 
IU/ml were achieved within a week of vector injection and were stably maintained until 
the mice were culled after four weeks. Six out of eight animals in the hIFN-β transduced 
cohort had no evidence of leukaemia when analysed by flow cytometry or 
immunohistochemistry. In contrast, all control mice (n=7) expressing human FIX after 
AAV mediated gene transfer had widespread evidence of leukaemic infiltration at levels 
observed in saline treated controls (n=6) (Figure 7.6). These experiments demonstrated 
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clearly that hIFN-β has a profound antileukaemic effect in vivo providing plasma levels 
of hIFN-β can be stably maintained.  
A 
 
 
B 
 
Figure 7.6 (A) HL-60 tumour burden in β2mnull NOD/SCID mice following AAV2/8 
hIFN-β gene transfer – quantitative results from FACS analysis of bone marrow and 
spleen single cell suspensions. Control animals included a saline treated cohort and a 
cohort receiving AAV2/8 hFIX vector. Error bars represent SEM (*p=0.003, 
**p=0.001) (B) Human CD45 immunohistochemistry confirming the widespread 
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tissue infiltration of control hFIX transduced mice with HL-60 cells, in marked 
contrast to hIFN-β transduced animals.  
 
We next attempted to compare the antileukaemic effects of hIFNα and hIFNβ in vivo. 
AAV2/8 hIFN-α or AAV2/8 hIFN-β vector was administered to cohorts of HL-60 
injected mice at a dose of 3×1010 vector particles per animal (n=4 each cohort). Despite 
the equivalent vector dose given, plasma levels of hIFNβ achieved was approximately 
twofold higher than plasma hIFNα levels (6000±400 and 3000±400 IU/ml respectively) 
(Figure 7.7). This variation in levels is likely to have arisen from differences in the 
biological activity of the two different vector stocks, which is not taken into account by 
the vector dose. Bone marrow tumour load in both hIFNα and hIFNβ cohorts was 
substantially lower (10.7±5.4% and 0.9±0.5% respectively) than in control FIX 
transduced animals (76.3±5%) (Figure 7.7). The higher residual tumour load in the hIFN-
α cohort compared with hIFN-β is probably a reflection of lower plasma hIFN-α levels 
although differences in antitumour activity in vivo between hIFN-α and hIFN-β, as 
observed in many solid tumors, cannot be excluded. Nevertheless we have shown that 
stable expression of both hIFN-α and β at supraphysiological levels, results in significant 
antileukemic activity against HL-60 cells in vivo which appears to be mediated (at least in 
part) through a pro-apoptotic mechanism. 
 
 
Figure 7.7 Plasma IFN-α/β levels measured by a functional antiviral assay (left). HL-
60 tumour burden in bone marrow from mice transduced with either control hFIX, 
AAV 2/8 hIFN-α or AAV 2/8 hIFN-β - results from FACS analysis. 
 
7.7 Stable expression of interferon-β inhibits primary AML cell proliferation in 
vivo  
118 
 
We next evaluated the effects of stable hIFN-β expression on the proliferation of primary 
AML cells in vivo. In separate sets of experiments, β2mnull NOD/SCID mice were 
implanted with 1x107 primary leukemic cells taken from 3 different patients with poor 
risk AML (high white cell count, Flt3-ITD mutation) followed, two weeks later, by 
transduction with 1×1011 vector particles of AAV2/8 hIFN-β or an equivalent dose of 
AAV2/8 hFIX. After six weeks mice were analysed and in all 3 experiments there was 
clear evidence of AML infiltration within the bone marrow of control animals (n=11) 
whereas none of the hIFN-β transduced mice (n=12) had any evidence of leukaemia 
(Table 7.2). Plasma levels of hIFN-β in these experiments ranged from 7000 to 90000 
IU/ml (median 48000 IU/ml).  
 
Table 7.2 Phenotypic characteristics of AML donors used in these experiments and 
outcome of engraftment studies following AAV2/8 mediated hIFN-β expression in 
vivo 
Proportion of mice engrafted with AML  Patient 
characteristics hFIX transduced hIFN-β  transduced 
Patient 1 AML M4 
Flt3/ITD+ve 
WBC 308 
3/3 0/4 
Patient 2 AML M1 
Flt3/ITD+ve 
WBC 150 
5/5 0/4 
Patient 3 AML M1 
Flt3/ITD+ve 
3/4 * 0/9 
• 1 death from radiation toxicity 
• Primary AML engraftment was defined as >1% tumour infiltration of bone 
marrow by CD45 FACS analysis 
 
In subsequent experiments three doses of AAV2/8 hIFN-β vector (1×1011, 1×1010 or 
1×109 particles/animal) were administered into cohorts of mice injected two weeks 
previously with primary AML cells. The degree of AML infiltration within bone marrow 
was found to correlate directly with mean plasma hIFN-β levels (Figure 7.8) with a 700-
fold and 140-fold reduction in tumor load at plasma hIFN-β levels of 55000 ± 12000 and 
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1500 ± 130 IU/ml respectively. Significantly a 50-fold reduction in primary AML 
infiltration was seen even when plasma levels were <10 IU/ml (4 ± 0.8 IU/ml). 
Pharmacokinetic studies in humans have shown a great deal of variability in plasma 
hIFN-β levels achieved following recombinant hIFN-β treatment but levels under 10 
IU/ml have been relatively well tolerated. 
 
A      B 
 
Figure 7.8 (A) Plasma hIFN-β levels in β2mnull NOD/SCID mice following AAV2/8 
mediated transduction at different vector doses. Measurements made in duplicates on two 
separate occasions. (B) Effects of plasma hIFN-β levels on primary AML proliferation in 
vivo - quantitative results from FACS analysis of bone marrow (p<0.01 at all vector doses 
compared with control) 
 
 
7.8 Antileukaemic effects of interferon-β in vivo – mechanisms of action 
The mechanisms of action underlying the antitumour activity of IFN-β include their direct 
antiproliferative and apoptotic effects on tumour cells as well as their immunomodulatory 
and antiangiogenic properties. The use of our immunodeficient β2mnullNOD/SCID model 
enabled us to selectively assess the anti-proliferative and proapoptotic effects of hIFN-β 
on AML cells in vivo in the absence of its immunomodulatory and direct anti-angiogenic 
properties as hIFN-β does not cross-react with its cognate murine receptor. We performed 
TUNEL staining on leukaemic tumours extracted from mice transduced with AAV2/8 
hIFNβ and showed increased apoptosis of HL-60 cells compared with tumours from 
control mice (Figure 7.8) in keeping with our in vitro observations. Attempts at assessing 
in vivo proliferation with the BrDu assay were not successful (data not shown). Our 
model did not allow us to examine the direct antiangiogenic effects of hIFNβ but its 
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potential indirect effects on murine angiogenesis, mediated by modulation of tumour 
secreted proangiogenic cytokines, were explored by staining murine vasculature. No 
significant differences, however, were seen in microvessel density between tumours from 
hIFNβ and FIX transduced animals (data not shown).  
 
 
Figure 7.9 TUNEL staining of subcutaneous HL-60 tumour implants following 
systemic transduction with AAV2/8 hFIX or AAV2/8 hIFN-β. The negative tumour 
control was stained without prior treatment with TdT enzyme. All slides were 
counterstained with DAPI 
 
7.9 Discussion 
The work presented in this chapter describes the effects of type I interferons (α and β) on 
AML cell proliferation and survival in vitro and in a xenograft model of AML. We have 
demonstrated that both IFN-α and IFN-β have profound but equivalent antiproliferative 
effects against a range of AML cell lines in vitro. This contrasts with the results from 
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previous studies where IFN-β has consistently been shown to be superior to IFN-α in its 
antitumour activity against a range of tumour cell lines. We have also shown that type I 
IFNs have a direct pro-apoptotic effect on AML cells and have proven that the biological 
effects of type I IFNs on AML cells are mediated, atleast partly, by the JAK/STAT 
signalling pathway. 
Our xenograft model of AML enabled us to study the effects of interferon-β on the 
proliferation of AML cells in vivo. The use of recombinant human IFN-β failed to 
demonstrate antileukaemic efficacy in vivo when administered either subcutaneously or 
intravenously, even when peak plasma levels of 200-1000 IU/ml were achieved with the 
intravenous route.  The most likely explanation for this lack of therapeutic benefit is the 
short half-life of IFN-β. Pharmacokinetic studies of IFN-β in humans have shown a half-
life of approximately five hours with either intravenous or subcutaneous administration 
(Salmon et al., 1996). It is therefore possible that even frequent parenteral administration 
of IFN-β may be insufficient to keep the interferon signalling pathway activated for long 
enough to result in an antileukaemic effect. The short half-life of recombinant IFN-β is 
consequently a significant limiting factor in clinical trials. Frequent or continuous 
administration protocols have to be used and the side effects associated with peak levels 
can often be debilitating. The only published randomized clinical trial of a type I 
Interferon in AML is that of the UK MRC AML11 trial (Goldstone et al., 2001) where 
low dose IFN-α (3MIU 3 times a week) was used as maintenance treatment in older 
patients with AML. No reduction in relapse rate or improvement in survival was shown. 
Of note was the poor compliance of patients, with only a third of patients able to tolerate 
the side effects of IFN-α and complete the full 12 months of treatment. An alternative to 
using recombinant protein is a gene therapy approach where systemic administration of a 
viral vector would result in transduction and stable low level expression of IFN-β in vivo. 
The use of AAV8 vectors ensured stable expression of IFN in vivo for the lifetime of the 
animals thereby circumventing the problem of the short half-life of IFNs. Our 
experiments clearly show that AAV mediated IFN-α and β expression significantly 
inhibits HL-60 proliferation and survival in vivo. We were unable to directly compare the 
antileukaemic effects of IFN-α and β in vivo because of difficulty in ensuring equivalent 
plasma levels of IFN between the two cohorts. We have also shown for the very first time 
conclusive evidence of the antitumour effects of IFN-β against primary AML cells in a 
xenograft model, even when samples from patients with poor prognostic features were 
used. In these experiments IFN-β gene therapy was initiated a full two weeks after 
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primary AML cell inoculation showing the effectiveness of IFN-β treatment despite 
tumour growth being fully established. Furthermore IFN-β was shown to have significant 
activity against primary AML cells in vivo at plasma levels less than 10 IU/ml, levels 
which have been shown to be tolerated well in humans. 
We have shown that the antitumour activity of IFN-β against leukaemic cells results 
primarily from its direct antiproliferative and pro-apoptotic properties. However our data 
also seem to indicate that the antileukaemic activity of  IFN-β in vivo is substantially 
greater than that seen in vitro, thus raising the possibility of other contributory 
mechanisms. The well known immunomodulatory properties of type I IFNs are unlikely 
to have played a role in our xenograft model in view of the immunodeficient nature of the 
β2mnull NOD/SCID mouse strain used. However type I IFNs are known to have 
antiangiogenic properties which could potentially play a role. Our use of human IFN-β in 
a murine system rules out a direct antiangiogenic effect because of the species specific 
nature of interferons. However an indirect antiangiogenic effect arising from 
downregulation of tumour secreted proangiogenic cytokines in response to IFN 
stimulation cannot be ruled out. Downregulation of tumour secreted proangiogenic 
factors bFGF, VEGF, MMP2 and MMP-9 in response to hIFN-β treatment has been 
demonstrated for a number of solid tumours but we have failed to show a similar effect 
with HL-60 leukaemic cells. Furthermore we have not shown any obvious difference in 
MVD in IFN-β treated animals. Another mechanism of action of hIFN-β is the 
normalisation of the disorganised vasculature of tumours mediated through angiopoietin-
1 upregulation, demonstrated in a glioma and neuroblastoma xenograft model following 
hIFN-β gene therapy (Dickson et al., 2007). We have however not been able to 
demonstrate such a phenomenon in our hIFN-β treated leukaemia mice. 
In summary, our study demonstrates that type I interferons α and β have significant 
activity against AML in the setting of a xenograft model. Detailed analysis with hIFN-β 
showed that sustained expression even at low but potentially clinically tolerable levels, 
achieved here by gene transfer, resulted in significant inhibition of leukemic cell 
proliferation in vivo. These results suggest that alternative delivery strategies such as the 
use of continuous intravenous or subcutaneous administration protocols or the longer 
acting pegylated form of IFN-β or a gene therapy approach may prove more effective in 
treating patients with AML. 
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8.1  Conclusions 
The aim of this thesis was to investigate the therapeutic effects of stable antiangiogenic 
expression in murine models of  Acute Myeloid Leukaemia, Multiple Myeloma and non-
Hodgkin’s Lymphoma. The hypothesis was that angiogenesis played a crucial role in the 
pathogenesis of haematalogical malignancies such as AML, MM and NHL through the 
provision of oxygen and nutrients to the proliferating tumour cells as well as by releasing 
a number of growth factors and cytokines and therefore blocking key angiogenic 
pathways would result in inhibition of tumour growth.  
It was essential to first develop appropriate murine models of the haematological 
malignancies we were targeting as antiangiogenic strategies are best evaluated in vivo 
where tumour associated neovasculature and the extracellular matrix are thought to play 
an important role in facilitating tumour progression. Prior to our work only few transgenic 
models existed for AML and lymphoma and none for myeloma. The xenograft models 
that had been developed were often orthotopic models that bore no resemblance to the 
human disease and the systemic models that were in use were often limited by unreliable 
disease phenotype. Commonly used immunodeficient mice strains for tumour 
engraftment included the NOD/SCID and B6 SCID strains. However as we have shown 
residual NK cell activity (seen in both these strains) can result in tumour rejection 
necessitating the use of irradiation or NK cell depleting antibodies. We have developed a 
range of xenograft models  of AML, B cell NHL and MM that closely mimic the human 
phenotype. The use of the β2mnull NOD/SCID strain which lacks B, T and NK cells 
enabled us to reliably engraft a range of haematological human tumour cell lines in vivo 
by tail vein injection of tumour cells without the need for additional irradiation. We have 
thus developed models for AML using the HL-60 cell line and importantly primary AML 
cells, MM using the ARH-77 and KMSBM cell lines and NHL using both Raji and U937 
cell lines. Important features of these models include the systemic nature of the disease, 
the predilection of the disease for infiltrating bone marrow as well as for causing bone 
lytic disease in the KMSBM myeloma model and the increased neovasculature seen at 
tumour sites. Furthermore the slower growth kinetics of the tumour in the primary AML 
and the KMSBM models makes them potentially more amenable to antiangiogenic 
strategies. 
As we have highlighted there are numerous naturally occurring pro and antiangiogenic 
molecules found naturally that usually exist in equilibrium. However under the influence 
of tumours this equilibrium is altered and the angiogenic switch is activated leading to 
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increased neovasulature which facilitates tumour progression. Based on the evidence at 
the time we decided to target two key angiogenic pathways – the vascular endothelial 
growth factor pathway and the matrix metalloproteinase pathway and to investigate the 
effects of blocking these pathways on tumour progression in AML, MM and NHL 
models. We also evaluated the effects of expressing human interferon-β, a cytokine with 
multiple mechanisms of action incuding antiangiogenesis, on AML cells in vivo. 
Experience from several clinical trials using antiangiogenic molecules and interferons had 
led to the conclusion that the short half-life of these agents potentially limited their 
efficacy. Furthermore cumbersome drug administration protocols had to be developed to 
overcome the pharmacokinetic obstacles associated with these agents. We therefore 
decided to investigate the effects of stably blocking angiogenesis by adopting a gene 
therapy based approach to ensure continuous expression of the antiangiogenic molecule. 
The use of AAV5 and 8 vectors enabled us to express our antiangiogenic genes of interest 
in vivo rapidly, at high levels and most importantly stably. We have shown that tail vein 
injection of  these vectors into immunodeficient mice, even at low doses, results in 
systemic protein expression as early as two weeks post transduction for AAV8 and 4 
weeks for AAV5.  Long term followup of these transduced mice shows persistent 
expression at high levels for atleast 6 months. The protocols for AAV production and 
purification developed collaboratively by members of our laboratory and Dr Davidoff’s 
group at St Jude’s Children’s Research Hospital have resulted in easy and reproducible 
generation of high titer virus free of contaminants. This has allowed us to readily evaluate 
the antitumour effects of a range of molecules in murine tumour models. Furthermore the 
AAV8 production methodology has since been further optimised and scaled up to 
generate clinical grade vector (AAV8-FIX) for a clinical trial in patients with haemophilia 
B. 
We have also optimised the method for producing lentiviral vectors which we have used 
very effectively to transduce a variety of haematological cell lines, some of which were 
historically difficult to transduce by other methods. We were able to generate high titer 
bicistronic lentiviral vectors which allowed us to express the antiangiogenic gene of 
interest as well as to use a reporter gene to track the transduced cells.  
Our experiments with blocking the VEGF pathway by expressing the soluble form of one 
of its key receptors (sFlk-1) failed to demonstrate antitumour efficacy in AML or 
lymphoma models, despite sFlk-1 being expressed at supraphysiological levels. An 
alternative strategy of using an antibody against VEGF also failed to produce a 
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therapeutic effect in the same tumour models. Paradoxically there appeared to be a trend 
towards greater tumour progression in animals given the antibody than in controls, atleast 
at lower doses. There are several potential explanations for these results. Firstly it may be 
that these tumour models are too aggressive for antiangiogenesis to be effective as a 
single treatment modality and it may need to be combined with other therapies to see an 
inhibition of tumour growth. Secondly as we have described there are other receptors for 
VEGF which may still be able to signal upon binding with their ligand. However we have 
also shown no therapeutic effect with an anti-VEGF antibody which in theory should 
prevent binding of VEGF to any of its receptors. A third possibility is the compensatory 
upregulation of VEGF production by host stromal tissue, a phenomenon described 
previously by Davidoff (Davidoff et al., 2005b). Finally it is possible that in our tumour 
models VEGF may not be the critical angiogenic factor and therefore blockade of this 
pathway fails to produce a desired therapeutic effect as other pro-angiogenic cytokines 
play a more prominent role. 
Previous clinical trials using matrix metalloproteinase inhibitors were largely 
unsuccessful at preventing tumour growth in several solid tumour types (Pavlaki and 
Zucker, 2003). However the use of the endogenous inhibitors of metalloproteinases 
(TIMPs) and in particular TIMP-3 had not previously been evaluated in AML or 
myeloma. We have shown for the first time significant antitumour effects when TIMP-3 
was stably expressed within KMSBM myeloma cells in vivo both in terms of degree of 
tumour infiltration and prolongation of survival. In contrast TIMP-3 expression in HL-60 
AML cells and ARH77 myeloma cells failed to result in any significant tumour 
regression. Possible explanations for these contrasting results include differences in the 
level of TIMP-3 expression between the different cell lines and potential differing roles 
played by the extracellular matrix in the different tumour models. 
We have also shown impressive antileukaemic effects against both AML cell lines as well 
as primary leukaemia cells from poor risk AML patients by expressing human interferon-
β continuously using AAV vectors in vivo. This is the first report of the therapeutic 
effects of hIFN-β against AML cells. Crucially we were able to demonstrate antitumour 
efficacy in vivo even at levels low enough to be clinically tolerable. In contrast 
recombinant human IFN-β failed to show any therapeutic effect against AML cells in 
vivo when administered either intraperitoneally or intravenously, despite adequate peak 
serum IFN-β levels being achieved by the intravenous route. Our data would suggest that 
maintenance of IFN-β levels is crucial for its antitumour effects and we would argue that 
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this could be achieved either by a gene therapy based approach or by the use of the 
pegylated form of recombinant hIFN-β. The main mechanisms of action of hIFN-β were 
found to antiproliferative and pro-apoptotic in this model although an indirect 
antiangiogenic effect could not be ruled out.  
In summary we have developed xenograft models for AML, NHL and MM and have been 
able to show in our myeloma model significant antitumour efficacy in vivo when the 
antiangiogenic factor TIMP-3 was expressed within KMSBM myeloma cells. In addition 
we have convincingly demonstrated for the first time marked antileukaemic efficacy with 
human interferon-β against HL-60 cells and more importantly against primary leukaemic 
cells when this cytokine was expressed stably in vivo using AAV vector mediated gene 
transfer. 
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